

REFINITIV

DELTA REPORT

10-Q

APLS - APELLIS PHARMACEUTICALS,

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 1654

■	CHANGES	223
■	DELETIONS	826
■	ADDITIONS	605

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, March 31, 2023** **2024**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from **to**

Commission File Number: **001-38276**

APELLIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

27-1537290

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

100 Fifth Avenue,
Waltham, MA
(Address of principal executive offices)

02451

(Zip Code)

Registrant's telephone number, including area code: **(617) 977-5700**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	APLS	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Small reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of **October 24, 2023** **May 1, 2024**, the registrant had **118,499,945** **121,365,555** shares of common stock, \$0.0001 par value per share, outstanding.

APELLIS PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, MARCH 31, 2023

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	3
Item 1. Financial Statements (Unaudited)	3

<u>Condensed Consolidated Balance Sheets as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023</u>	3
<u>Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss) for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023</u>	4
<u>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023</u>	5
<u>Condensed Consolidated Statements of Cash Flows for the nine three months ended September 30, 2023 March 31, 2024 and 2022 2023</u>	76
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	87
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	23 20
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	37 31
<u>Item 4. Controls and Procedures</u>	38 31
PART II. OTHER INFORMATION	39 32
<u>Item 1A. Risk Factors</u>	39 32
<u>Item 5. Other Information</u>	42 32
<u>Item 6. Exhibits</u>	43 34
<u>Signatures</u>	44 35

[Table of Contents](#)

Special Note Regarding Forward-Looking Statements and Industry Data

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

- the ongoing commercialization of EMPAVELI and SYFOVRE;

- our plans with respect to our ongoing and planned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials;
- our sales, marketing and distribution capabilities and strategies, including for the commercialization and manufacturing of EMPAVELI, SYFOVRE and any future products;
- the rate and degree of market acceptance and clinical utility of EMPAVELI, SYFOVRE and any future products;
- our ongoing review of the reported events of retinal vasculitis following SYFOVRE treatment;
- our plans to develop our current and future product candidates for any additional indications;
- the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
- the potential clinical benefits and attributes of our current and future product candidates we may develop and the inhibition of C5;
- our current and any future collaborations for the development and commercialization of our current and future product candidates;
- the potential benefits of any current or future collaboration, including our collaborations with Sobi and Beam Therapeutics, Inc.;
- the rate and degree of market acceptance and clinical utility of EMPAVELI, SYFOVRE and any other products for which we receive marketing approval;
- our commercialization, marketing and manufacturing capabilities and strategy;
- our intellectual property position and strategy;
- our ability to identify additional products or product candidates with significant commercial potential;
- our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- the impact of our recent restructuring and anticipated cost savings and operational efficiencies;
- developments relating to our competitors and our industry; and
- the impact of new government laws and regulations (including tax).

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 31, 2023, particularly in the "Risk Factors" section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed or incorporated by reference as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

[Table of Contents](#)

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. All of the market data used in this Quarterly Report on Form 10-Q involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. We believe that the information from these industry publications, surveys and studies is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Quarterly Report on Form 10-Q, December 31, 2023. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. The Apellis, EMPAVELI, SYFOVRE and Apellis Assist names and logos are our trademarks, trade names and service marks. The other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

Note regarding certain references in this Quarterly Report on Form 10-Q

Unless otherwise stated or the context indicates otherwise, all references herein to "Apellis," "Apellis Pharmaceuticals, Inc.," "we," "us," "our," "our company," "the Company" and similar references refer to Apellis Pharmaceuticals, Inc. and its wholly owned subsidiaries.

In addition, unless otherwise stated or the context indicates otherwise, all references in this Quarterly Report on Form 10-Q to "EMPAVELI (pegcetacoplan)" and "EMPAVELI" refer to **systemic** pegcetacoplan in the context of the commercially available product in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH, and references to Aspaveli refer to **systemic** pegcetacoplan in the context of the commercially available product in the European Union for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months, in each case, as more fully described herein. Unless otherwise stated or the context indicates otherwise, all references in this Quarterly Report on Form 10-Q to "SYFOVRE (pegcetacoplan injection)" and "SYFOVRE" refer to intravitreal pegcetacoplan in the context of the commercially available product for which we received approval from the United States Food and Drug Administration in February 2023 for the treatment of geographic atrophy secondary to age-related macular degeneration. Unless otherwise stated or the context indicates otherwise, all references herein to "pegcetacoplan" refer to pegcetacoplan in the context of the product candidate for which we are exploring further applications and indications, as more fully described herein. The other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

[Table of Contents](#)

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

APELLIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Amounts in thousands, except per share amounts)

	September	December	March 31, 2024	December 31, 2023
	30, 2023	31, 2022		
	2023	2022		
Assets				
Current assets:				
Cash and cash equivalents	\$ 452,414	\$ 551,801	\$ 325,923	\$ 351,185
Accounts receivable	169,258	7,727		
Accounts receivable, net			267,837	206,442
Inventory	98,545	85,714	161,283	146,362
Prepaid assets	44,617	36,350	43,163	38,820
Restricted cash	1,086	1,273	1,103	1,114
Other current assets	30,847	36,658	12,119	22,408
Total current assets	796,767	719,523	811,428	766,331
Non-current assets:				
Right-of-use assets	15,484	18,747	14,994	16,745
Property and equipment, net	4,790	6,148	4,195	4,345
Other assets	1,175	15,799	1,313	1,309
Total assets	<u>\$ 818,216</u>	<u>\$ 760,217</u>	<u>\$ 831,930</u>	<u>\$ 788,730</u>
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	\$ 18,192	\$ 37,342	\$ 26,788	\$ 37,516
Accrued expenses	117,089	95,139	101,399	127,806
Current portion of development liability	44,610	29,504	77,287	75,830
Current portion of right-of-use liabilities	5,739	5,625		
Current portion of lease liabilities			6,257	6,441
Deferred Revenue			3,560	—
Total current liabilities	185,630	167,610	215,291	247,593
Long-term liabilities:				
Long-term development liability	295,532	315,647	244,426	239,817
Convertible senior notes	92,957	92,736	93,109	93,033
Right-of-use liabilities	10,880	14,352		
Lease liabilities			9,770	11,454
Other liabilities	946	—	2,658	2,312
Total liabilities	<u>585,945</u>	<u>590,345</u>	<u>565,254</u>	<u>594,209</u>

Stockholders' equity:			
Preferred stock, \$0.0001 par value; 10,000 shares authorized, and zero			
shares issued and outstanding at September 30, 2023 and December 31, 2022	—	—	
Common stock, \$0.0001 par value; 200,000 shares authorized at September 30, 2023 and December 31, 2022; 118,359 shares issued and outstanding at September 30, 2023, and 110,772 shares			
issued and outstanding at December 31, 2022	12	11	
Preferred stock, \$0.0001 par value; 10,000 shares authorized, and zero			
shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—	
Common stock, \$0.0001 par value; 200,000 shares authorized at March 31, 2024 and December 31, 2023; 121,267 shares issued and outstanding at March 31, 2024, and 119,556 shares issued and outstanding at December 31, 2023			
	12	12	
Additional paid-in capital	2,982,23	2,479,59	
	6	6	
Accumulated other comprehensive loss	(1,065)	(875)	
	(2,748,9	(2,308,8	
Accumulated deficit	12)	60)	
	(2,903,911)	(2,837,488)	
Total stockholders' equity	232,271	169,872	
	266,676	194,521	
Total liabilities and stockholders' equity	\$ 818,216	\$ 760,217	
	\$ 831,930	\$ 788,730	

See accompanying notes to unaudited condensed consolidated financial statements

3

[Table of Contents](#)

APELLIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) LOSS
(Unaudited)
(Amounts in thousands, except per share amounts)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,		For the Three Months Ended March 31,	
	2023	2022	2023	2022	2024	2023
Revenue:						
Product revenue, net	\$ 99,182	\$ 17,676	\$ 6	\$ 45,439	\$ 163,075	\$ 38,800
Licensing and other revenue	11,217	4,380	22,588	7,320	9,250	6,046
	110,39		250,21			
Total revenue:	9	22,056	4	52,759	172,325	44,846
Operating expenses:						
Cost of sales	22,410	1,381	38,598	2,711	20,209	7,809
Research and development	79,421	95,207	5	3	84,701	110,027
	145,64		359,11	192,79		
General and administrative	8	78,406	4	5		
Selling, general and administrative					129,505	102,093
	247,47	174,99	682,81	483,31		
Total operating expenses:	9	4	7	9	234,415	219,929
	(137,0	(152,9	(432,6	(430,5		
Net operating loss	80)	38)	03)	60)	(62,090)	(175,083)
		(32,89		(32,89		
Loss on conversion of debt	—	0)	—	0)		
Interest income	4,989	2,809	16,385	4,339	3,303	5,393
			(22,17	(24,88		
Interest expense	(7,310)	(7,903)	9)	8)	(6,967)	(7,529)
Other (expense)/income, net	(603)	99	(946)	(42)		
Other (expense)/ income, net					(499)	(277)
	(140,0	(190,8	(439,3	(484,0		
Net loss before taxes	04)	23)	43)	41)	(66,253)	(177,496)
Income tax expense	233	446	709	2,140	170	282
	(140,2	(191,2	(440,0	(486,1		
Net loss	\$ 37)	\$ 69)	\$ 52)	\$ 81)	\$ (66,423)	\$ (177,778)
Other comprehensive gain/(loss):						
Unrealized gain/(loss) on marketable securities	—	435	—	(383)		

Foreign currency loss	(269)	(268)	(190)	(554)		
Total other comprehensive income/(loss)	(269)	167	(190)	(937)		
Foreign currency translation					17	100
Total other comprehensive income					17	100
Comprehensive loss, net of tax	(140,5	(191,1	(440,2	(487,1		
	\$ 06)	\$ 02)	\$ 42)	\$ 18)	\$ (66,406)	\$ (177,678)
Net loss per common share, basic and diluted	\$ (1.17)	\$ (1.75)	\$ (3.73)	\$ (4.65)	\$ (0.54)	\$ (1.56)
Weighted-average number of common shares used in net loss per common share, basic and diluted	120,29	109,12	117,82	104,60		
	2	6	7	8	122,957	113,872

See accompanying notes to unaudited condensed consolidated financial statements

4

Table of Contents

APELLIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

(Unaudited)

(Amounts in thousands)

	Inco						me/(Eq					
	Sha	Amo	Capi	Los	Defi	uit	Shares	Amount	Capital	Income/(Loss)	Deficit	Equity						
	res	unt	tal	s)	cit	y												
				2,				(2	1									
	1			4				,3	6									
	1			7				0	9									
	0,			9,				8,	,									
Balance at	7			5	(8			8	8									
January 1,	7	1	9	7	6	7												
2023	2	\$ 1	\$ 6	\$ 5)	\$ 0)	\$ 2												
Issuance of																		
common									3									
stock and				3					8									
pre-funded				8					4									
warrants in	4,		4,			,												
common	0		3						3									
stock	0		8						8									
offering	8	1	6	—	—	7												
Balance at																		
January 1,																		
2024																		
Proceeds																		
from																		
settlement																		
of capped																		
call																		
Issuance of									1									
common				1					7									
stock upon				7,					,									
exercise of	9		7						7									
stock	5		1						1									
options	1	—	8	—	—	8		714	—		9,477						9,477	
Vesting of									(
restricted									1									
stock units,				(1					0									
net of				0,					,									
shares	4		9						9									
withheld for	4		9						9									
taxes	8	—	9)	—	—	9)		997	—		(28)						(28)	

Share-based compensation expense	2,822	2,888	2,882	2,822	—	—	30,349	—	—	30,349
Unrealized gain on available-for-sale investments	—	—	—	—	—	—	—	—	—	—
Net loss	—	—	—	—	8)	8)	—	—	—	(66,423)
Foreign currency gain	—	—	—	—	0	—	—	—	—	(66,423)
Balance at March 31, 2023	1,792	5,273	(7,631)	1,824	2,888	2,882	—	—	—	—
Issuance of common stock upon exercise of stock options	1,220	2,303	—	—	—	—	—	—	—	—
	0	3	—	—	—	—	—	—	—	—
	8	—	4	—	—	—	4	—	—	—

Vesting of restricted stock units, net of						
shares	1					(
withheld for	1		(2			2
taxes	9	—	7)	—	—	7)
						2
			2			9
Share- based compensati on expense	—	—	7	—	—	7
Issuance of common stock to employee stock purchase plan						3
			3,			,
			7			7
	7		5			5
	3	—	4	—	—	4
						(
						1
						(1
						2
						2
						2,
						,
						0
						0
						3
Net loss	—	—	—	—	—	7)
Foreign currency loss	—	—	—	—	—	7)
						(
						2
	—	—	—	—	—	1)
						—
			2,			1)
						3
	1		9		,6	4
	1		5		0	5
	7,		4,		8,	,
Balance at	5		8	(7	6	4
June 30,	7	1	6	9	7	0
2023	9	\$ 2	\$ 2	\$ 6)	\$ 5)	\$ 3

Issuance of						
common			5			
stock upon	5,		,			
exercise of	6	7	7			
stock	6	5	5			
options	5	—	7	—	—	7
Vesting of						
restricted						
stock units,						
net of						
shares	1					
withheld for	1		(
taxes	5	—	(9)	—	—	9)
						2
			2			1
Share-		1,	,			
based		6	6			
compensati		2	2			
on expense	—	—	6	—	—	6
						(
						1
			(1	4		
			4	0		
			0,	,		
			2	2		
			3	3		
Net loss	—	—	—	—	7)	7)
						(
Foreign			(2			2
currency			6			6
loss	—	—	—	9)	—	9)
			2,		(2	2
	1		9		,7	3
	1		8		4	2
	8,		2,	(1	8,	,
Balance at	3		2	,0	9	2
September	5	1	3	6	1	7
30, 2023	9	\$ 2	\$ 6	\$ 5)	\$ 2)	\$ 1

Foreign						
currency						
translation						
	—	—	—	—	17	—
						17

Balance at							
March 31,							
2024	<u>121,267</u>	<u>12</u>	<u>3,174,100</u>	<u>(3,525)</u>	<u>(2,903,911)</u>	<u>266,676</u>	

See accompanying notes to unaudited condensed consolidated financial statements

[Table of Contents](#)

APELLIS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Continued from previous page)

(Unaudited)

(Amounts in thousands)

Acc umu lated						Accumulated				
Common	Stock	tion	Othe	Tot	Common Stock	Additional	Other		Total	
Out		Com		Sto						
sta		preh	Acc	ckh						
ndi	Paid	ensi	umu	old						
ng	-In	ve	lated	ers'	Outstanding	Paid-In	Comprehensive	Accumulated	Stockholders'	
					Eq					
					uity					
					(De					
Sha	Amo	Capi	Defi	ficit					Equity	
res	unt	tal	Loss)	Shares	Amount	Capital	Loss	(Deficit)	
					1					
					9					
		1,		(1	8					
		85		,6	,					
Balance at	97	7,	(2	56	6					
January 1,	,5	1	43	,0	,6					
2022	24	\$ 0	\$ 0	\$ 90)	\$ 88)	\$ 2				

Common	38	,	3
Stock -	8,	0,	8
follow-on-	56	11	0
offering	4	1	0
Balance at			
January 1,			
2023	110,772	\$ 11	\$ 2,479,596
			\$ (875) \$ (2,308,860) \$ 169,872
Issuance			
of			
common			
stock and			
pre-			
funded			
warrants			
in			
common			
stock			
offering	4,008	1	384,386
			—
			384,387
Issuance			
of			
common			
stock	4	,	
upon			
exercise	4,	0	
of stock	23	00	
options	9	—	0
			951
			—
			17,718
Vesting of			
restricted			
stock			(
units, net			2
of shares			,
withheld			(2
for taxes	11	,4	4
			1
			448
			—
			(10,999)
			—
			(10,999)

Share-based compensation expense	—	—	73	—	—	3	—	—	28,823	—	—	28,823
Unrealized gain on available-for-sale investments	—	—	—	—	—	—	(52)	—	—	—	—	—
Net loss	—	—	—	—	—	35)	5)	—	—	—	(177,778)	(177,778)
Foreign currency gain	—	—	—	—	83	—	—	—	—	—	—	—
Balance at March 31, 2022	6,440	1,100	9,900	0,050	(2,050)	5,620	2,300	(1,279)	79,790	—	—	—
Issuance of common stock upon exercise of stock options	—	—	—	—	—	—	—	—	—	—	—	—

Vesting of restricted stock units,						
net of					(
shares					5	
withheld				(5		3
for taxes	26	—	36)	—	6)	
					2	
Share- based compensat					2	
ion				,5		3
expense	—	—	30	—	0	
Issuance of common stock to employee					2	
stock				,2		5
purchase				53		3
plan	92	—	1	—	1	
Unrealized loss on available- for-sale investment				(
s	—	—	—	66)	6)	
				(
				1		
				5		
				5		
				(1		
				,55		9
				,9		7
Net loss	—	—	—	—	77)	7)
				(
Foreign currency loss					3	
				(3		6
	—	—	—	69)		9)

						3
						3
		2,		(1,		4
	10	28		95		,
Balance at	6,	9,	(3,	1,		4
June 30,	84	1	20	19	60	1
2022	1	\$ 1	\$ 1	\$ 4)	\$ 0)	\$ 8
Issuance						
of shares						
in						
exchange						1
of						2
Convertible						9
Notes,		12				,
including	3,	9,				6
issuance	07	63				3
costs	3	—	6	—	—	6
Forfeiture						
of accrued						
interest in						1
exchange						,
of		1,				2
Convertible		28				8
Notes	—	—	7	—	—	7
Issuance						1
of common						0
stock upon						,
exercise of		10				6
stock	52	,6				3
options	1	—	39	—	—	9
Vesting of						(
restricted						
stock units,						1
net of						,
shares		(1,				0
withheld		00				0
for taxes	41	—	3)	—	—	3)

						2
Share- based compensat ion expense	—	—	23	—	—	3
Unrealized loss on available- for-sale investment	—	—	—	41	—	5
	—	—	—	—	—	4
	—	—	—	—	—	1
	—	—	—	—	—	1
	—	—	—	—	—	4
	—	—	—	—	—	3
	—	—	—	—	—	5
	—	—	—	—	—	(
	—	—	—	—	—	1
	—	—	—	—	—	9
	—	—	—	—	—	1
	—	—	—	—	—	(1
	—	—	—	—	—	,
	—	—	—	—	—	91
	—	—	—	—	—	2
	—	—	—	—	—	,2
	—	—	—	—	—	6
Net loss	—	—	—	—	—	69)
	—	—	—	—	—	9)
	—	—	—	—	—	(
Foreign currency loss	—	—	—	—	—	2
	—	—	—	—	—	6
	—	—	—	—	—	8)
	—	—	—	—	—	3
	—	—	—	—	—	0
	—	—	—	—	—	2,
	—	—	—	—	—	(2,
	—	—	—	—	—	7
	—	—	—	—	—	,
Balance at September 30, 2022	0,	1	30	02	86	11
	47	6	\$ 1	\$ 1	\$ 7)	\$ 9)
	—	—	—	—	—	6
Foreign currency translation	—	—	—	—	—	100
Balance at March 31, 2023	116,179	12	2,899,524	(775)	(2,486,638)	412,123

See accompanying notes to unaudited condensed consolidated financial statements

[Table of Contents](#)

APELLIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)

	For the Nine Months Ended		For the Three Months Ended March 31,	
	September 30,		2024	
	2023	2022	2024	2023
Operating Activities				
Net loss	\$ (440,052)	\$ (486,181)	\$ (66,423)	\$ (177,778)
Adjustments to reconcile net loss to net cash used in operating activities:				
Share-based compensation expense	79,726	66,844	30,349	28,823
Loss on conversion of debt	—	32,890		
Forfeiture of accrued interest in exchange of convertible notes	—	1,287		
Loss on disposal of fixed assets	152	—	—	19
Amortization of right-of-use assets	(94)	(105)		
Depreciation expense	1,308	1,164	444	421
Amortization of discounts for convertible notes, net of financing costs	222	386		
Amortization of discounts for convertible notes			76	73
Accretion of discount to development liability	19,491	20,053	6,066	6,633
Other liabilities	—	1,938		
Changes in operating assets and liabilities:				
Accounts receivable	(161,542)	2,010	(61,415)	(23,778)
Inventory	(12,831)	(43,436)	(14,921)	144
Prepaid assets	(7,681)	(5,492)	(4,338)	(107)
Other current assets	5,981	45,457	10,697	2,308
Other assets	14,811	15,885	98	14,969
Right-of-use assets and lease liabilities			(116)	(22)
Accounts payable	(19,450)	(4,437)	(10,730)	(5,854)
Accrued expenses	23,099	(21,264)	(26,330)	(23,471)

Deferred revenue			3,560	—
Net cash used in operating activities	(496,860)	(373,001)	(132,983)	(177,620)
Investing Activities				
Purchase of property and equipment	(678)	(673)	(293)	(259)
Purchase of available-for-sale securities	—	(331,863)		
Proceeds from maturity of available-for-sale securities	—	268,300		
Net cash (used in) provided by investing activities	(678)	(64,236)		
Net cash used in investing activities			(293)	(259)
Financing Activities				
Proceeds from issuance of common stock, net of issuance costs	384,387	380,120		
Payments for development liability	(24,500)	(16,500)		
Proceeds from settlement of capped call			98,763	—
Proceeds from issuance of common stock and pre-funded warrant offering, net of issuance costs			—	384,387
Proceeds from exercise of stock options	45,809	19,409	9,477	17,718
Proceeds from issuance of common stock under employee share purchase plan	3,754	2,531		
Payment of employee tax withholding related to equity-based compensation	(11,038)	(3,955)		
Payments of employee tax withholding related to equity-based compensation			(28)	(10,999)
Net cash provided by financing activities	398,412	381,605	108,212	391,106
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(449)	(675)	(209)	56
Net increase (decrease) in cash, cash equivalents and restricted cash	(99,575)	(56,307)		
Net (decrease) increase in cash, cash equivalents and restricted cash			(25,273)	213,283
Cash, cash equivalents and restricted cash at beginning of period	553,075	641,755	352,299	553,075
Cash, cash equivalents and restricted cash at end of period	\$ 453,500	\$ 585,448	\$ 327,026	\$ 766,358
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:				
Cash and cash equivalents	\$ 452,414	\$ 584,189	\$ 325,923	\$ 765,083
Restricted cash	1,086	1,259	1,103	1,275

Total cash, cash equivalents, and restricted cash	\$ 453,500	\$ 585,448	\$ 327,026	\$ 766,358
Supplemental Disclosures				
Cash paid for interest	\$ 3,286	\$ 5,003	\$ 1,643	\$ 1,643
Cash paid for income taxes	\$ 578	\$ 156	—	\$ 250
Convertible Notes exchanged for common stock	—	98,086		
Proceeds from income tax refunds net of income taxes paid			257	—

See accompanying notes to unaudited condensed consolidated financial statements

76

[Table of Contents](#)

APELLIS PHARMACEUTICALS, INC. **NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** **(unaudited)**

1. Nature of Organization and Operations

Apellis Pharmaceuticals, Inc. (the "Company") is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company's principal executive offices are located in Waltham, Massachusetts.

The Company's operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH") and the **commercializing** **commercialization** of SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration ("GA").

The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company's products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration ("FDA").

Liquidity and Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. From inception to **September 30, 2023** **March 31, 2024**, the Company has incurred cash outflows from operations, losses from operations and had an accumulated deficit of **\$2.7** **2.9** billion primarily as a result of expenses incurred through a combination of research and development activities related to **our** **the Company's** various product candidates and expenses supporting those activities. The Company has primarily financed its operations through public offerings of its common stock, convertible debt, private placements of preferred stock prior to its initial public offering, the development funding agreement with SFJ Pharmaceuticals Group ("SFJ"), and the collaboration agreement with Sobi. The Company has financed a portion of its operations through product sales but has not yet achieved profitability.

As of **November 1, 2023** **May 7, 2024**, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of **\$452.4** **325.9** million as of **September 30, 2023** **combined** **March 31, 2024** together with its cash flows anticipated to be generated from sales of **EMPAVELI** and from **SYFOVRE** will be sufficient to fund its operations and capital expenditures **expenditure requirements** for at least the next twelve months.

The Company's future viability beyond that point is dependent on its ability to achieve commercial success for **SYFOVRE** and **EMPAVELI**. There are uncertainties associated with the Company's ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission (the "SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted and, accordingly, the condensed consolidated balance sheet as of **December 31, 2022** **December 31, 2023** has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of the Company's financial **results for the interim periods presented**, **information**. The results of operations for the three **and nine** months ended **March 31, 2024** are not

months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 December 31, 2024 or for any other interim period or for any other future year.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2022 December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on February 21, 2023 February 27, 2024, as amended by Amendment No. 1 thereto filed with the SEC on February 29, 2024 (the "2022 "2023 Form 10-K").

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development liability, accrued expenses, prepaid expenses, convertible debt, reserves for variable consideration, reserves for excess or obsolete inventories, and income taxes.

Summary of Significant Accounting Policies

Reference is made to Note 2 Summary of Significant Accounting Policies in our 2022 2023 Form 10-K for a detailed description of significant accounting policies. There have been no significant changes to our accounting policies as disclosed in our 2022 2023 Form 10-K.

Recently Issued Accounting Standards

In December 2023, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on income taxes which requires entities to provide additional information in the rate reconciliation and additional disaggregated disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and disclosures.

In November 2023, the FASB issued an amendment to the accounting guidance on segment reporting. The amendments require disclosure of significant segment expenses and other segment items and requires entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The amendment also requires disclosure of the title and position of the chief operating decision maker ("CODM") and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15,

2024. Retrospective application is required, and early adoption is permitted. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements.

3. Product Revenues, Accounts Receivable, and Reserves for Product Sales

The Company received FDA approval for the sale of EMPAVELI in the United States in May 2021 and approval for the sale of SYFOVRE in the United States in February 2023. The Company's product revenues, net of sales discounts, and allowances and reserves, for the three months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** were **\$99.2** **163.1** million and **\$17.7** million, respectively. The Company's product revenues, net of sales discounts and allowances and reserves, for the nine months ended **September 30, 2023** and **2022** were **\$227.6** million and **\$45.4** **38.8** million, respectively. The Company's product revenues consist of sales of EMPAVELI and SYFOVRE to specialty pharmacies and specialty distributors.

The table reflects product revenue by major source for the following periods (in thousands):

Products:	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023		2022	
EMPAVELI	\$ 23,901	\$ 17,676	\$ 66,643	\$ 45,439
SYFOVRE	75,281	—	160,983	—
Total Product revenue, net	\$ 99,182	\$ 17,676	\$ 227,626	\$ 45,439

8

Table of Contents

Products:	Three Months Ended March 31,	
	2024	
EMPAVELI	\$ 25,610	\$ 20,440
SYFOVRE	137,465	18,360
Total Product revenue, net	\$ 163,075	\$ 38,800

The Company's accounts receivable balance of **\$169.3** **267.8** million as of **September 30, 2023** **March 31, 2024** and **\$7.7** **206.4** million as of **December 31, 2022** **December 31, 2023**, consisted of EMPAVELI and SYFOVRE product sales receivable and licensing and other revenue receivables from our collaboration with Swedish Orphan Biovitrum AB (Publ) ("Sobi"). The Company does not have a reserve related to expected credit losses against its accounts receivable balance and expects to collect its accounts receivable in the ordinary course of business.

The Company's product sales reserves totaled \$10.319.2 million and \$2.416.6 million as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively. These amounts are included in accrued expenses on the Company's unaudited condensed consolidated balance sheet.

sheets.

The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended **September 30, 2023** **March 31, 2024** and 2023 (in thousands):

	Chargebacks,	Government and		Returns	Total
	Discounts, and Fees	other rebates			
Ending balance at December 31, 2023	\$ 5,674	\$ 8,898		\$ 2,053	16,625
Provision related to sales in the current year	9,575	13,125		1,355	24,055
Adjustments related to prior period sales	146	(19)		(96)	31
Credits and payments made	(9,724)	(9,906)		(1,859)	(21,489)
Ending balance at March 31, 2024	<u>\$ 5,671</u>	<u>\$ 12,098</u>		<u>\$ 1,453</u>	<u>\$ 19,222</u>

9

Table of Contents

	Chargeback	Governme			Chargebacks, Discounts, and			Government and other		
	Discounts,	other	Ret		Fees		rebates	Returns	Total	
	and Fees	rebates	s	Total						
Ending balance at December 31, 2022	\$ 164	\$ 1,936	\$ 1	1	\$ 164		\$ 1,936	\$ 251	2,351	
Provision related to sales in the current year					4,					
					65	68				
	1,466	2,566	1	3		1,466		2,566	651	4,683
Adjustments related to prior period sales					(2					
					4	(2				
	—	(2)	9)	51)		—		(2)	(249)	(251)
Credits and payments made					(1					
					,8					
	(184)	(1,639)	—	23)		(184)		(1,639)	—	(1,823)
Ending balance at March 31, 2023	\$ 1,446	\$ 2,861	\$ 3	\$ 0	\$ 1,446		\$ 2,861	\$ 653	\$ 4,960	

Provision		1,		
related to sales		5	10	
in the current		8	,6	
year	3,944	5,114	8	46
Adjustments		(4		
related to prior		1	(4	
period sales	(84)	30	6)	70)
Credits and		(1	(4	
payments		4	,7	
made	(1,668)	(2,946)	1)	55)
Ending balance		1,		
at June 30, 2023		6	10	
		8	,3	
	\$ 3,638	\$ 5,059	\$ 4	\$ 81
Provision		1,		
related to sales		3	13	
in the current		8	,2	
year	4,698	7,169	4	51
Adjustments		(1		
related to prior		,6	(2	
period sales		8	,6	
	39	(964)	5)	10)
			(1	
Credits and		0,		
payments		73		
made	(4,960)	(5,778)	—	8)
Ending balance		1,		
at September		3	10	
30, 2023		8	,2	
	\$ 3,415	\$ 5,486	\$ 3	\$ 84

Significant customers - Gross product revenues and product sales receivable from the Company's customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total product sales receivable consisted of the following:

Percent of Total Gross Product Revenues				Percent of Total Gross Product Revenues	
Three Months Ended		Nine Months Ended		Three Months Ended March 31,	
September 30,		September 30,		2024	
2023	2022	2023	2022		2023

Customer A	24 %	99 %	29 %	99 %	15%	52%
Customer C	16 %	—	14 %	—	19%	9%
Customer D	56 %	1 %	52 %	1 %	59%	33%

	Percent of Product Sales Receivable		Percent of Product Sales Receivable	
	As of September 30,		As of March 31,	
	2023	2022	2024	2023
Customer A	7 %	97 %	3%	25%
Customer C	19 %	—	21%	15%
Customer D	68 %	3 %	67%	52%

[Table of Contents](#)

4. Inventory

The Company's inventory consisted of the following as of **September 30, 2023**, **March 31, 2024** and **December 31, 2022** **December 31, 2023** (in thousands):

	September 30,		December 31,	
	2023	2022	2024	2023
Raw materials	\$ 26,150	\$ 29,847	\$ 42,089	\$ 32,724
Semi-finished goods	52,110	54,101		
Finished goods	20,285	1,766		
Total Inventories	\$ 98,545	\$ 85,714		
	March 31,		December 31,	
	2024	2023	2024	2023
Raw materials	\$ 42,089	\$ 32,724		

Semi-finished goods	106,161	82,924
Finished goods	13,033	30,714
Total Inventory	<u>\$ 161,283</u>	<u>\$ 146,362</u>

Inventory amounts written down as a result of excess, obsolete, unmarketability or other reasons are charged to cost of sales. The Company's reserve for excess and obsolete inventory was \$7.9 million and \$9.3 million as of March 31, 2024 and December 31, 2023, respectively.

5. Prepaid and Other Current Assets

Prepaid and other current assets consisted of the following as of September 30, 2023, March 31, 2024 and December 31, 2022 December 31, 2023 (in thousands):

	September 30,		March 31,		December 31,	
	2023	2022	2024	2023	2023	2023
Down payments for inventory	\$ 16,723	\$ 13,987	13,828			16,296
Prepaid research and development	15,244	15,181	12,626			13,931
Other prepaid expenses	12,650	7,182	16,709			8,593
Total prepaid expenses	<u>\$ 44,617</u>	<u>\$ 36,350</u>	<u>\$ 43,163</u>			<u>\$ 38,820</u>

	March 31,		December 31,	
	2024	2023	2023	2023
Royalties receivable	\$ 4,499		\$ 3,054	
Receivable from collaboration agreement(1)	—		15,000	
Deposits and other current assets	7,620		4,354	
Total other current assets	<u>\$ 12,119</u>		<u>\$ 22,408</u>	

10

(1) In January 2024 the Company waived the remaining reimbursement payment of \$15.0 million from Sobi in connection with the decision to discontinue the cold agglutinin disease (CAD) program.

Table of Contents

	September 30,		December 31,	
	2023	2022	2022	2023
Royalties receivable	\$ 2,731	\$ 1,442		
ERC credit	—	8,711		
Receivable from collaboration agreement	15,000	20,000		
Deposits and other current assets	13,116	6,505		
Total other current assets	<u>\$ 30,847</u>	<u>\$ 36,658</u>		

Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") signed into law on March 27, 2020 and the subsequent extension of the CARES Act, the Company was eligible for a refundable employee retention credit ("ERC") subject to certain criteria. The ERC provides eligible employers with less than 500 employees a refundable tax credit against the employer's share of social security taxes. The ERC is equal to 70% of qualified wages paid to employees during 2021 calendar year for a maximum credit of \$7,000 per employee for each calendar quarter through September 30, 2021. In November 2022, the Company filed for an \$8.7 million refund under the CARES Act relating to the ERC. The full refund amount was received as of June 30, 2023.

6. Development Liability

On February 28, 2019, the Company entered into a development funding agreement with SFJ (the "SFJ agreement"), with SFJ Pharmaceuticals Group ("SFJ"), under which SFJ agreed to provide funding to the Company to support the development of pegcetacoplan for the treatment of patients with PNH. Pursuant to the SFJ agreement, SFJ paid the Company \$60.0 million following the signing of the agreement and agreed to pay the Company up to an additional \$60.0 million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Company's Phase 3 program for pegcetacoplan in PNH. PNH and subject to the Company having cash resources at the time sufficient to fund at least 10 months of the Company's operations.

On June 7, 2019, In June 2019 the Company and SFJ amended the SFJ agreement (such amendment, the "SFJ amendment"). Under the SFJ amendment, SFJ agreed to make include an additional \$20.0 million funding payment to payment. SFJ paid the Company to support the development of systemic pegcetacoplan for the treatment of patients with PNH.

As of January 29, 2020, the Company had received a total of \$140.0 80.0 million from under the amended SFJ as the Company met milestones as identified in the SFJ agreement. The Company did not receive any additional funds from SFJ after January 29, 2020. agreement between June 2019 and January 2020.

Under the SFJ agreement, following regulatory approval by the FDA in May 2021 for the use of systemic pegcetacoplan as a treatment for PNH, the Company became obligated to pay SFJ an initial payment of \$4.0 million and then an additional \$226.0 million in the aggregate in six additional annual payments with the majority of the payments being made from the third anniversary to the sixth anniversary of regulatory approval. The Company paid SFJ the initial payment of \$4.0 million in June 2021, its first annual payment of \$11.5 million in May 2022 and its second annual payment of \$24.5 million in May 2023. The subsequent annual payments remaining are due and payable in May of each year from 2024 through 2027.

Table of Contents

Following regulatory approval of systemic pegcetacoplan for the treatment of PNH by the European Medicines Agency ("EMA") in December 2021, the Company became obligated to pay SFJ an initial payment of \$5.0 million and then an additional \$225.0 million in the aggregate in six additional annual payments with the majority of the payments being made from the third anniversary to the sixth anniversary of regulatory approval. The Company paid SFJ the initial payment of \$5.0 million in January 2022 and the its first annual

payment of \$18.0 million in December 2022, 2022 and its second annual payment of \$31.0 million in December 2023. The subsequent annual payments are due and payable in December of each year from 2023 2024 through 2027.

The Company has paid SFJ a total of \$63.0 94.0 million as of September 30, 2023 March 31, 2024. The Company is obligated to pay SFJ \$37.5 million in May 2024 and \$61.3 million in December 2024.

Additionally, the Company granted a security interest to SFJ in all of its assets, excluding intellectual property and license agreements to which it is a party. In connection with the grant of the security interest, the Company agreed to certain affirmative and negative covenants, including restrictions on its ability to pay dividends, incur additional debt or enter into licensing transactions with respect to its intellectual property, other than specified types of licenses.

From December 15, 2021 to the final annual payment due in December 2027, the development liability will be accreted from its initial carrying amount to the total payment amount using the effective interest rate method under the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 835, *Interest*, over the remaining life of the SFJ agreement. The difference between the carrying amount and the total payment amount is presented as a discount to the development liability. The accretion is recorded as interest expense in the unaudited condensed consolidated statement of operations.

The following table summarizes the development liability (in thousands):

11

[Table of Contents](#)

	Effective			Effective		
	September 30, 2023	December 31, 2022	Interest Rate			Interest Rate
				March 31, 2024	December 31, 2023	
Development liability	\$ 397,000	\$ 421,500	7.91%	\$ 366,000	\$ 366,000	7.91%
Less: Unamortized discount to development liability	(56,858)	(76,349)		(44,287)	(50,353)	
Less: Current portion of development liability, net of discount	(44,610)	(29,504)		(77,287)	(75,830)	
Total long term development liability	<u>\$ 295,532</u>	<u>\$ 315,647</u>				
Total long-term development liability				<u>\$ 244,426</u>	<u>\$ 239,817</u>	

For the three and nine months ended September 30, 2023, March 31, 2024 and 2023 interest expense of \$6.4 6.1 million and \$19.5 6.6 million respectively, was were recorded for the accretion of the development liability.

Future minimum SFJ payments as of September 30, 2023 are March 31, 2024 is as follows (in thousands):

2023	\$ 31,000		
2024		\$ 98,750	\$ 98,750
2025		103,000	103,000
2026		109,000	109,000
2027		55,250	55,250

Total future minimum payments	\$ <u>397,000</u>	366,000
-------------------------------	-------------------	---------

7. Accrued Expenses

Accrued expenses consisted of the following as of **September 30, 2023** **March 31, 2024** and **December 31, 2022**, **December 31, 2023** (in thousands):

	September 30, 2023	December 31, 2022	March 31, 2024	December 31, 2023
	\$ 35,133	\$ 34,849	\$ 22,912	\$ 28,318
Accrued research and development				
Accrued royalties	10,720	907	6,224	10,197
Accrued payroll liabilities	40,415	43,212	20,789	51,781
Accrued goods received not invoiced			15,829	5,902
Product revenue reserves			19,222	16,625
Other	30,821	16,171	16,423	14,983
Total	\$ 117,089	\$ 95,139	\$ 101,399	\$ 127,806

On August 29, 2023, the Company announced a corporate restructuring plan to drive the growth of SYFOVRE and EMPAVELI and position the Company. As part of this plan, the Company reduced headcount by approximately 25% across the organization, and such reductions were substantially completed in the three months ended September 30, 2023. Costs incurred in connection with the restructuring plan consisted of one-time termination benefits to employees who were involuntarily terminated. The Company expensed the employee termination costs immediately on the communication date of the restructuring plan as future services are not required. For the three months ended September 30, 2023, the Company incurred \$10.0 million in employee termination costs, which is recorded in operating expenses in the consolidated statements of operation. As of September 30, 2023, \$5.7 million was included in accrued payroll liabilities to be paid. [11](#)

[Table of Contents](#)

8. Long-term Debt

Convertible Senior Notes

On September 16, 2019, the Company completed a private offering of convertible notes (the "2019 Convertible Notes") with an aggregate principal amount of \$220.0 million issued pursuant to an indenture (the "Indenture") with U.S. Bank National Association, as

trustee.

The net proceeds from the sale of the 2019 Convertible Notes were approximately \$212.9 million after deducting the initial purchasers' discounts and commissions of \$6.6 million and offering expenses of \$0.5 million paid by the Company. The Company used \$28.4 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the capped call transactions in September 2019 described below.

On May 12, 2020, the Company issued convertible notes (the "2020 Convertible Notes") with an aggregate principal amount of \$300.0 million. The net proceeds from the sale of the 2020 Convertible Notes were approximately \$322.9 million after deducting the

[Table of Contents](#)

purchasers' discounts and commission of \$5.7 million and offering expenses of \$0.3 million. The Company used \$43.1 million of the net proceeds from the sale of the 2020 Convertible Notes to pay the cost of the additional capped call transactions in May 2020 described below.

The 2019 Convertible Notes and the 2020 Convertible Notes are referred to together as the Convertible Notes. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 3.5% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2020. The Convertible Notes will mature on September 15, 2026, unless converted earlier, redeemed or repurchased in accordance with their terms.

The Convertible Notes are convertible into shares of the Company's common stock at an initial conversion rate of 25.3405 shares per \$1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately \$39.4625 per share of common stock). The conversion rate is subject to customary anti-dilution adjustments. In addition, following certain events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or a notice of redemption, as the case may be, in certain circumstances as provided in the Indenture.

Prior to March 15, 2026, the Convertible Notes are convertible only under the following circumstances:

- during any calendar quarter, if the last reported sale price of the Company's common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
- during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Convertible Notes for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day;
- if the Company calls any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or
- upon the occurrence of corporate events specified in the Indenture.

On or after March 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders may convert the Convertible Notes at any time regardless of the foregoing circumstances. Upon

conversion of the Convertible Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or a combination of cash and shares of common stock, at the Company's election.

Prior to September 20, 2023, the Company could not redeem the Convertible Notes. From and after September 20, 2023, the Company may redeem for cash all or a portion of the Convertible Notes, at its option, if the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides a notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company calls any Convertible Notes for redemption, it will constitute a "make-whole fundamental change" with respect to such Convertible Notes, in which case the conversion rate applicable to

[Table of Contents](#)

the conversion of such Notes, if converted in connection with the redemption, will be increased in certain circumstances. The Company has not called for redemption or redeemed any of the Convertible Notes as of **September 30, 2023** **March 31, 2024**.

If the Company undergoes a "fundamental change," as defined in the Indenture, prior to maturity, subject to certain conditions, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Company used an effective interest rate of 10.5% to determine the liability component of the 2019 and 2020 Convertible Notes. This resulted in the recognition of \$145.1 million and \$204.5 million as the liability component of the 2019 and 2020 Convertible Notes, respectively, and the recognition of the residual amount of \$74.9 million and \$95.5 million as the debt discount with a corresponding increase to additional paid in capital for the equity component of the 2019 and 2020 Convertible Notes, respectively. The 2020 Convertible Notes aggregate debt issuance costs of \$6.0 million were allocated to the liability and equity components in the amounts of \$3.7 million and \$2.3 million, respectively. The 2019 Convertible Notes aggregate debt issuance costs of \$7.1 million were allocated to the liability and equity components in the amounts of \$4.7 million and \$2.4 million, respectively.

Effective January 1, 2021, the Company adopted Accounting Standards Update 2020-06 using the modified retrospective method.

Upon adoption, the Company increased net debt and reduced net equity by \$149.7 million. The \$149.7 million consisted of several

[Table of Contents](#)

items. The first item is the reclassification from equity to debt of the residual amounts originally identified as the equity components of the 2019 and 2020 Convertible Notes of \$74.9 million and \$95.5 million, respectively. The equity component reclassification was offset by the adjustment to retained earnings for the reversal of previous non-cash interest expense recorded for the amortization of the

equity components of \$17.1 million. The second item is the reclassification from equity to debt of the debt issuance costs originally allocated to equity for the 2019 and 2020 Convertible Notes of \$2.4 million and \$2.3 million, respectively. The debt issuance costs reclassification was offset by the adjustment to retained earnings for previous amortization of the debt issuance costs recorded of \$1.1 million.

In January 2021, July 2021 and July 2022, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of its 2019 Convertible Notes and 2020 Convertible Notes. Under the terms of these exchange agreements, in January 2021, July 2021 and July 2022, the holders exchanged approximately \$126.1 million of 2019 Convertible Notes, \$201.1 million of 2019 Convertible Notes and 2020 Convertible Notes, and \$98.1 million of 2020 Convertible Notes, respectively, in aggregate principal amount held by them for an aggregate of 3,906,869 shares, 5,992,217 shares and 3,027,018 shares, respectively, of common stock issued by the Company. In accordance with FASB ASC Topic 470-20, "Debt" – Debt with Conversion and Other Options," ("ASC 470-20") the Company accounted for the exchange as an induced conversion based on the short period of time the conversion offer was open and the substantive conversion feature offer. The Company accounted for the conversion of the debt as an inducement by expensing the fair value of the shares that were issued in excess of the original terms of the Convertible Notes.

As a result of the January 2021 exchange transactions, the Company reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$122.8 million, consisting of the par value of the 2019 Convertible Notes exchanged of \$126.1 million less the \$3.3 million of remaining debt issuance costs associated with the exchanged notes. The Company also increased shares outstanding by 3,906,869 shares consisting of 3,196,172 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 710,697 shares. Additionally, the Company issued 69,491 shares as settlement of debt issuance costs paid to the Company's financial advisor in connection with the exchange transaction. For the three months ended March 31, 2021, the Company recorded a loss on conversion of debt of \$39.5 million comprised of \$36.4 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$3.1 million for the value of the 69,491 shares issued in payment of issuance costs at their then fair value. Upon exchange of the 2019 Convertible Notes, the holders forfeited accrued interest through the date of the exchange of \$1.7 million, which the Company charged to interest expense and to equity.

As a result of the July 2021 exchange transactions, the Company reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$197.0 million, consisting of the par value of the Convertible Notes exchanged of \$201.1 million less the \$4.1 million of remaining debt issuance costs associated with the exchanged notes. The Company also increased shares outstanding by 5,992,217 shares consisting of 5,097,166 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 895,051 shares. Additionally, the Company issued 78,419 shares as settlement of issuance costs paid to the Company's financial advisor in connection with the exchange transaction. For the three months ended September 30, 2021, the Company recorded a loss on conversion of debt of \$61.1 million comprised of \$55.9 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$5.2 million for the value of the 78,419 shares issued in payment of issuance costs at their then fair value. Upon exchange of the Convertible Notes, the holders forfeited accrued interest through the date of the exchange of \$2.5 million, which the Company charged to interest expense and to equity.

As a result of the July 2022 exchange transactions, the Company reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$96.8 million, consisting of the par value of the Convertible Notes exchanged of \$98.1 million less the \$1.3 million of remaining debt issuance costs associated with the exchanged notes. The Company also increased shares outstanding by 3,027,018 shares consisting of 2,485,548 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 541,470 shares. Additionally, the Company issued 46,132 shares as settlement of issuance costs paid to the Company's financial advisor in connection with the exchange transaction. For the three months ended September 30, 2022, the Company recorded a loss on conversion of debt of \$32.9 million comprised of \$30.4 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$2.5 million for the value of the 46,132 shares.

The conditional conversion feature of the Convertible Notes was triggered as of **June 30, 2021** **December 31, 2023**, and as a result the Convertible Notes were convertible at the option of the holders until **September 30, 2021** **March 31, 2024**. During this period, certain holders of the **No** Convertible Notes **were** converted approximately \$0.7 million of aggregate principal amount of Convertible Notes into an aggregate of 18,775 shares, which were issued in October 2021, during this period.

The conditional conversion feature of the Convertible Notes was triggered as of **March 31, 2023** **March 31, 2024**, and as a result the Convertible Notes **were** **are** convertible at the option of the holders until **June 30, 2023** **June 30, 2024**. No Convertible Notes were converted during this period.

The conditional conversion feature of the Convertible Notes was triggered as of June 30, 2023, and as a result the Convertible Notes **were** **are** convertible at the option of the holders until September 30, 2023. No Convertible Notes were converted during this period.

[Table of Contents](#)

As of **September 30, 2023** **March 31, 2024**, the Company held in treasury Convertible Notes in principal amount of \$425.4 million which notes **had** **have** not been cancelled.

The outstanding balance of the Convertible Notes as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023** consisted of the following (in thousands):

	September 30,	December 31,	March 31,	December 31,
	2023	2022	2024	2023
Liability				
Principal	93,897	93,897	93,897	93,897
Less: debt discount and issuance costs, net	(940)	(1,161)	(788)	(864)
Net carrying amount	\$ 92,957	\$ 92,736	\$ 93,109	\$ 93,033

The following table sets forth total interest expense recognized related to the Convertible Notes during the three **and** **nine** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** (in thousands):

	Three Months				Nine Months Ended		Three Months Ended March 31,	
	Ended		September 30,		September 30,		March 31,	
	September 30,	2023	September 30,	2022	September 30,	2023	September 30,	2022
	2023	2022	2023	2022	2023	2022	2023	2022
Amortization of debt		1,08						
issuance costs	\$ 75	\$ 8	\$ 222	\$ 4,448			76	73
Contractual interest		82						
expense	2	97	2,465	386			822	822
	89	1,18						
Total interest expense	\$ 7	\$ 5	\$ 2,687	\$ 4,834	\$	898	\$	895

Future minimum payments on Convertible Notes payable as of **September 30, 2023** **March 31, 2024** are as follows (in thousands):

2023	\$ 822	
2024	3,286	\$ 2,465
2025	3,286	3,286
2026	96,225	96,225
Total future minimum payments	103,619	101,976
Less: interest	(9,722)	(8,079)
Less: debt discount and issuance costs, net	(940)	(788)
Less: current portion	—	—
Convertible senior notes	\$ 92,957	93,109

13

[Table of Contents](#)

Capped Call Transactions

On **September 11, 2019** **September 11, 2019** and May 6, 2020, concurrently with the pricing of the **2019** Convertible Notes **and the 2020** Convertible Notes, respectively, the Company entered into capped call transactions with two counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company's common stock upon any conversion of Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Convertible Notes, as the case may be, in the event that the market price per share of the Company's common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which is initially \$39.4625 (the conversion price of the Convertible Notes) and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such Convertible Notes. If, however, the market price per share of the Company's common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, which is initially \$63.14 per share, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

Pursuant to FASB ASC Topic 815-40 Derivatives and Hedging,

On February 27, 2024, the Company **determined that** entered into agreements with the capped call counterparties to unwind a portion of the capped call transactions. The unwind transactions were settled based on the volume-weighted average price of the Company's common stock over a 7-day averaging period beginning on and including February 27, 2024. The settlement of the unwind transactions was completed on March 8, 2024 at volume-weighted average price per share of \$64.11, which resulted in cash proceeds to the Company of \$98.8 million. As of March 31, 2024, the capped call transactions **should be classified as equity instruments and the capped call premium paid in the remaining is a notional amount corresponding to \$93.9 million principal amount of \$28.4 million and**

\$43.1 million were recorded as reductions to additional paid-in capital at December 31, 2021 for the 2019 Convertible Notes and the 2020 Convertible Notes, respectively. [Notes](#).

9. Leases

The underlying assets of the Company's leases primarily relate to office space leases, but also include some equipment leases. The Company determines if an arrangement qualifies as a lease at its inception.

15

[Table of Contents](#)

As a practical expedient permitted under FASB ASC Topic 842, *Leases*, the Company elected to account for the lease and non-lease components as a single lease component for all leases of which it is the lessee. Lease payments, which may include lease and non-lease components, are included in the measurement of the Company's lease liabilities to the extent that such payments are either fixed amounts or variable amounts that depend on a rate or index as stipulated in the lease contract. When the Company cannot readily determine the rate implicit in the lease, the Company determines its incremental borrowing rate by using the rate of interest that it would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.

The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company's lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company's existing operating leases.

As of [September 30, 2023](#) [March 31, 2024](#) and [December 31, 2022](#) [December 31, 2023](#), all leases were classified as operating lease assets and liabilities. [leases](#). Additional information related to the operating lease assets and liabilities is as follows (in thousands):

	September		December		March 31, 2024	December 31, 2023		
	30, 2023		31, 2022					
	2023	2022	2024	2023				
Operating Lease Assets	\$ 15,484	\$ 18,747						
Right-of-use assets			\$ 14,994	\$ 16,745				
Operating Lease Liabilities	\$ 16,619	\$ 19,977	\$ 16,027	\$ 17,895				
Weighted Average Remaining Term in years	2.92	3.57	2.64	2.83				
Weighted Average discount rate used to measure								
outstanding lease liabilities	7.21 %	7.26 %	7.25 %	7.20 %				

For the three months ended [September 30, 2023](#) [March 31, 2024](#) and [2022](#), [2023](#), the total lease cost for operating lease expense was \$1.8 [1.5](#) million and \$1.7 million, respectively. For the nine months ended September 30, 2023 and 2022, the total lease cost for operating lease expense was \$5.2 million and \$4.6 million, respectively.

Supplemental cash flow information related to operating leases for the **nine** **three** months ended **September 30** **March 31, 2024** and **2023** **and 2022** is as follows (in thousands):

	2023	2022
Operating cash flows from operating leases	\$ 6,186	\$ 5,499
Operating lease assets obtained in exchange for lease obligations	\$ —	\$ —
	2024	2023
Operating cash flows from operating leases	\$ 2,311	\$ 2,022

The maturities of the Company's operating lease liabilities as of **September 30, 2023** **March 31, 2024** are as follows (in thousands):

2023	1,778	
2024	6,471	5,352
2025	5,329	6,188
2026	4,388	5,278
2027 and thereafter	<u>556</u>	
2027		858
Total future minimum lease payments	18,522	17,676
Less Imputed interest	<u>(1,903)</u>	<u>(1,649)</u>
Total operating lease liabilities	<u>\$ 16,619</u>	<u>\$ 16,027</u>

14

[Table of Contents](#)

10. Other Comprehensive Income and Accumulated Other Comprehensive Income

The following tables summarize the changes in accumulated other comprehensive income/(loss), by component for the **nine** **months** ended **September 30, 2023** and **2022** (in thousands):

16

[Table of Contents](#)

	Unrealized				Total Accumulated Comprehensive Income (Loss)
	Gains (Losses)	Foreign	Unrealized		
	from	Currency	Gains (Losses)	Other	
	Marketable	Translation	from Pension		
	Securities	Adjustment	Plan		
Balances, December 31, 2022	—	\$ (2,521)	\$ 1,646	\$ (875)	
Net other comprehensive income (loss)	—	100	—	100	
Balances, March 31, 2023	—	(2,421)	1,646	(775)	
Net other comprehensive loss	—	(21)	—	(21)	
Balances, June 30, 2023	—	(2,442)	1,646	(796)	
Net other comprehensive income (loss)	—	(269)	—	(269)	
Balances, September 30, 2023	\$ —	\$ (2,711)	\$ 1,646	\$ (1,065)	

	Unrealized Gains				Accumulated Other Comprehensive Income (Loss)
	(Losses) from	Foreign	Currency		
	Marketable	Translation			
	Securities	Adjustment			
Balances, December 31, 2021	\$ 1	\$ (2,091)	\$ (2,090)		
Net other comprehensive income (loss)	(52)	83	31		
Balances, March 31, 2022	(51)	(2,008)	(2,059)		
Net other comprehensive loss	(766)	(369)	(1,135)		
Balances, June 30, 2022	(817)	(2,377)	(3,194)		
Net other comprehensive income (loss)	435	(268)	167		
Balances, September 30, 2022	\$ (382)	\$ (2,645)	\$ (3,027)		

11. Fair Value Measurements

The Company is required to disclose information on the fair value of financial instruments and inputs that enable an assessment of the fair value. The three levels of the fair value hierarchy prioritize valuation inputs based upon the observable nature of those inputs as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly;

Level 3 – Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability.

The following table presents the fair value of financial instruments recorded originally at amortized cost or fair value and not remeasured on a recurring basis (in thousands):

September 30, 2023					
Balance Sheet Classification	Type of Instrument	Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents	Money market funds	\$ 310,969	\$ —	\$ —	\$ 310,969
Total Financial Assets		<u>\$ 310,969</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 310,969</u>

December 31, 2022					
Balance Sheet Classification	Type of Instrument	Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents	Money market funds	\$ 527,728	\$ —	\$ —	\$ 527,728
Total Financial Assets		<u>\$ 527,728</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 527,728</u>

March 31, 2024					
Balance Sheet Classification	Type of Instrument	Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents:	Money market funds	\$ 231,740	\$ —	\$ —	\$ 231,740
Total Financial Assets		<u>\$ 231,740</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 231,740</u>

December 31, 2023					
Balance Sheet Classification	Type of Instrument	Level 1	Level 2	Level 3	Total
Financial Assets:					
Cash and cash equivalents	Money market funds	\$ 276,391	\$ —	\$ —	\$ 276,391
Total Financial Assets		<u>\$ 276,391</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 276,391</u>

The Company's Convertible Notes and development liability are financial instruments that are reported in the consolidated financial statements at historical cost. The Convertible Notes are Level 1 within the fair value level hierarchy as of September 30, 2023 March 31, 2024 and December 31,

[Table of Contents](#)

2022 December 31, 2023. The fair value of the Convertible Notes was \$118.8 151.7 million as of September 30, 2023 March 31, 2024 and \$143.9 140.8 million as of December 31, 2022 December 31, 2023. The Convertible Notes accrue a semi-annual coupon at an annual rate of 3.5%, which was included in accrued expenses in the condensed consolidated balance sheets as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023.

The fair value of the development liability was \$333.8 million and \$316.9 million as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively. The development liability is Level 2 within the fair value hierarchy based on the discounting of fixed cash flows using an observed bond yield for borrowers with similar credit rating.

12.15

[Table of Contents](#)

11. Income Taxes

For the three and nine months ended **September 30, 2023**, **March 31, 2024** and **2023**, the Company recorded \$0.2 million and \$0.7 million of income tax expense, respectively, primarily pertaining to state and foreign income taxes.

The income tax provision during interim periods is computed by applying an estimated annual effective tax rate to year-to-date pre-tax income, plus adjustments for significant unusual or infrequently occurring items, in accordance with FASB ASC Topic 740-270, *Income Taxes – Interim Reporting*. The income tax provision differs from the U.S. federal statutory rate of 21% primarily due to the effect of valuation allowance against the Company's net deferred tax assets, which reduces the Company's net tax benefit.

Deferred tax assets and deferred tax liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance against its net deferred tax assets for the period ended **September 30, 2023** **March 31, 2024**.

The Company does not recognize a tax benefit for uncertain tax positions unless it is more likely than not that the position will be sustained upon examination by tax authorities, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of cumulative benefit that has greater than a 50 percent likelihood of being realized upon ultimate settlement. Deferred tax assets that do not meet these recognition criteria are not recorded and the Company recognizes a liability for uncertain tax positions that may result in tax payments. The Company has not recorded any amounts for unrecognized tax benefits positions for the period ended **September 30, 2023** **March 31, 2024**. If such unrecognized tax benefits were realized, the entire amount would impact the tax provision. Our policy is to review and update unrecognized tax positions as facts and circumstances change.

13.12. License and Collaboration Agreements

Sobi License and Collaboration Agreement

On October 27, 2020, **In October 2020**, the Company and its subsidiaries, Apellis International GmbH(f/k/a Apellis Switzerland GmbH) and APL DEL Holdings, LLC, entered into a Collaboration and License Agreement (the "Sobi collaboration agreement") with Sobi, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar

compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration (collectively referred to as the "Licensed Products").

Under the Sobi collaboration agreement, the Company granted Sobi an exclusive (subject to certain retained rights of the Company), sublicensable license of certain patent rights and know-how to develop and commercialize Licensed Products in all countries outside of the United States.

The Company retains the right to commercialize Licensed Products in the United States, and, subject to specified limitations, to develop Licensed Products worldwide for commercialization in the United States.

Under the Sobi collaboration agreement, the Company and Sobi have agreed to collaborate to develop Licensed Products for the treatment of PNH, CAD, HSCT-TMA, C3G, IC-MPGN and IC-MPGN, ALS (collectively the "Initial Indications"), and any other indications subsequently agreed upon by the parties, for commercialization by or on behalf of the Company in the United States and by or on behalf of Sobi outside of the United States. If the parties do not agree to jointly pursue any development activities for the Licensed Products (whether for an Initial Indication or otherwise), the party proposing to pursue such activities may conduct such activities at its sole expense (with the non-proposing party having the right to obtain rights to the data generated by such development activities by paying a specified percentage of that expense), subject to agreed-upon exceptions that limit each party's unilateral development rights.

The initial development plan sets forth the initial development activities to be conducted by each of the Company and Sobi, with the Company bearing all costs incurred in conducting the activities set forth in such initial development plan, as well as certain specified additional costs that are not included in the initial development plan that may be incurred by the parties in developing Licensed

18

[Table of Contents](#)

Products for PNH in the European Union and the United Kingdom. The Company and Sobi have formed several governance committees to oversee the development and manufacture, and to review and discuss the commercialization, of Licensed Products.

The Company and SOBI discontinued the development programs in ALS and CAD.

The Company shall supply Licensed Products to Sobi for development and for commercialization outside of the United States in accordance with a supply agreement to be negotiated by between the parties. The Sobi collaboration agreement grants Sobi the right to perform or have

16

[Table of Contents](#)

performed drug product manufacturing of Licensed Products for development and for commercialization outside the United States and to manufacture or have manufactured drug substance under certain circumstances.

Sobi paid the Company an upfront payment of \$250.0 million in November 2020 and has agreed to pay up to an aggregate of \$915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, of which the Company received \$50.0 million in April 2022 for the achievement of a regulatory development milestone in Europe and \$5.0 million in October 2023 for the

achievement of a regulatory development milestone in Japan. Europe. Sobi also agreed to reimburse the Company for up to \$80.0 million in development costs, of which the Company received \$25.0 million in January 2021, \$20.0 million in January 2022 and \$20.0 million in January 2023. The remaining waived payment of \$15.0 million is due from Sobi in January 2024. The Company will also be entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales of Licensed Products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable Licensed Product, in each case on a Licensed Product-by-Licensed Product and country-by-country basis. Under the Sobi collaboration agreement, the Company remains responsible for its license fee obligations (including royalty obligations) to the Trustees of the University of Pennsylvania ("Penn"), as a licensor of the Company and for its payment obligations to SFJ.

Sobi Accounting Analysis

The Company has determined that the Sobi collaboration agreement is within the scope of FASB ASC Topic 808, *Collaborative Arrangement Guidance and Considerations* ("ASC 808"), as a contractual arrangement that involves a joint operating activity whereby both parties are (i) active participants in the activity and (ii) exposed to certain significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not address measurement or recognition matters but allows for analogizing to FASB ASC Topic 606, *Revenue from Contracts with Customers* ("ASC 606"). Pursuant to ASC 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligations in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligations in the contract; and (v) recognized revenue when (or as) the entity satisfies a performance obligation.

The Company identified the following material distinct promises under the Sobi collaboration agreement: (1) licenses to develop and commercialize pegcetacoplan ("Licenses to IP"), and (2) performance of research and development services. The Company determined the promises to be distinct because Sobi can benefit from each of the license and the development services on their own or with readily available services. The Company could have provided the license without any development services and Sobi would have been able to benefit from it by obtaining development services from another provider as the Licensed Products are at a more mature stage in their life cycle.

Under the Sobi collaboration agreement, Sobi agreed to pay the Company

- i) a fixed amount of \$250.0 million in an upfront payment in November 2020;
- ii) a fixed amount of an additional \$80.0 million in development reimbursements, payable yearly in four tranches in amounts determined based upon actual expenses incurred by the Company;
- iii) up to an aggregate of \$915.0 million upon the achievement of specified one-time regulatory and commercial milestone events; and
- iv) tiered, double-digit royalties, ranging from high teens to high twenties, on sales of Licensed Products outside of the United States, subject to customary deductions and third-party payment obligations.

At contract inception, the \$250.0 million non-refundable payment and the \$80.0 million reimbursements were fixed proceeds. The Company evaluated whether Sobi is a customer for either of the distinct promises in the Sobi collaboration agreement. Under the Licenses to IP, the Company determined that Sobi is a customer as the know-how provided and the right granted by the Company to Sobi are outputs of the Company's business activities for which the Company will receive consideration. With respect to research and development activity, management determined that there is no vendor relationship as performing research and development activities for others is not a part of the Company's ongoing central operations. Based upon the evaluation of the relative fair values, the Company allocated the purchase price of \$250.0 million and the related milestones and royalties to the License to IP and \$80.0 million to performance of research and development activities.

Table of Contents

The milestone and royalty payments are subject to activities outside the control of the Company. Per ASC 606, the Company considers this to be a customer/ vendor relationship, therefore, the Company will include the regulatory milestone payments in the total transaction price when it is probable that a significant reversal of revenue would not occur in a future period. The Company will recognize commercial milestone and royalty revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which the commercial milestone or royalty has been allocated has been satisfied. In case of commercial milestone or royalty payments, the Company will recognize revenue in the same period that the sales are completed for which the Company is contractually entitled to the milestone or percentage-based royalty payment. To date, the Company has not recognized any commercial milestone revenue resulting from any of its licensing arrangements. The Company has recognized \$2.7 million and \$6.8 million of royalty revenue for the three and nine months ended September 30, 2023, respectively. Management periodically assesses the elements of the contract and re-evaluates revenue recognition as necessary.

Pursuant to ASC 606, during the year ended December 31, 2020, the Company recognized the \$250.0 million in revenue as this is the amount allocated to the license. The \$80.0 million reimbursement for research and development activities does not constitute a customer/vendor relationship and thus is not in the scope of ASC 606. As ASC 808 does not include recognition guidance, the Company has established an accounting policy to recognize the payments under the reimbursement as a receivable on the balance sheet in an amount that is to be reimbursed based upon expense incurred by the Company, with a contra- research and development expense recognized in the consolidated statement of operations, over time as the expenses are incurred.

Under the Sobi collaboration agreement, for the three and nine months ended September 30, 2023, March 31, 2024 and 2023, the Company recognized \$2.7 million and \$6.8 million, respectively, of royalty revenue. For the three and nine months ended September 30, 2022, the Company recognized \$0.8 million and \$1.6 million respectively, of royalty revenue. For the three and nine months ended September 30, 2023, the Company did not recognize any contra-research and development expense in the unaudited condensed consolidated statement of operations related to the \$80.0 million reimbursement commitment from Sobi. For the nine months ended September 30, 2022, the Company recognized \$5.0 million for contra-research and development expense in the unaudited condensed consolidated statement of operations related to the \$80.0 million reimbursement commitment from Sobi. revenue, respectively. The Company did not recognize any contra-research and development expense for the three months ended September 30, 2022, March 31, 2024 and 2023. Since contract inception, the Company has recognized \$65.0 million in contra-research and development expenses.

As of September 30, 2023 December 31, 2023, the Company recorded \$15.0 million in current assets, which represents the receivable for contra-research and development expenses incurred but not yet reimbursed from Sobi.

As of December 31, 2022, In January 2024, the Company recorded a receivable waived the remaining reimbursement payment of \$35.0 million, with \$20.0 million in other current assets and \$15.0 million in other assets on connection with the consolidated balance sheet. The total receivable balance as of December 31, 2022 is for contra-research and development expenses incurred but not yet reimbursed from Sobi. The Company received decision to discontinue the \$20.0 million recorded in other current assets in January 2023. CAD program.

University of Pennsylvania License Agreement

The Company is a party to a license agreement with Penn for an exclusive, worldwide license to specified patent rights in the ophthalmic field of use. The Company is required to pay annual maintenance fees of \$0.1 million until the first sale of a licensed product. The Company is also required to make milestone payments aggregating up to \$3.2 million based upon the achievement of specified development and regulatory milestones and up to \$5.0 million based upon the achievement of specified annual sales milestones with respect to each licensed product, and to pay low single-digit royalties based on net sales of each licensed product and with minimum quarterly royalty thresholds. In addition, the Company is obligated to pay a specified portion of income it receives from sublicensees.

In April 2023, the Company paid \$2.3 million for the achievement of a regulatory milestone as a result of the FDA approval of SYFOVRE in February 2023. Additionally, as of September 30, 2023, In 2023, the Company recorded in accrued expenses incurred \$5.0 million as a result of the achievement of sales milestones for SYFOVRE, SYFOVRE of which the Company paid \$2.0 million in October 2023 and the remaining \$3.0 million in January 2024.

As of September 30, 2023 March 31, 2024, the Company has incurred an aggregate royalty expense of \$8.3 13.4 million on sales of SYFOVRE.

In addition, the Company is also party to a license agreement with Penn for an exclusive, worldwide license to specified patent rights for the development and commercialization of products in nonophthalmic fields of use, as defined therein. The Company is required to pay annual maintenance fees of \$0.1 million until the first sale of a licensed product. The Company is required to make milestone payments aggregating up to \$1.7 million, based upon the achievement of development and regulatory approval milestones, and up to \$2.5 million, based upon the achievement of annual sales milestones with respect to each of the first two licensed products. The license agreement also requires the Company to pay low single digit royalties based on net sales of each licensed product, subject to minimum quarterly royalty thresholds. In addition, the Company is obligated to pay a specified portion of income it receives from sublicensees.

20

[Table of Contents](#)

In January 2021, the Company paid \$25.0 million for a sublicense fee owed to Penn related to the Sobi collaboration agreement and another licensing transaction. In August 2021, the Company paid \$1.0 million to Penn upon the achievement of a development milestone, net of a credit for the annual license maintenance payment. In June 2022, the Company paid an additional \$5.0 million to Penn upon the achievement of a development milestone. In January 2023, the Company paid \$1.0 million to Penn upon the achievement of a sales milestone for EMPAVELI in 2022. In September 2023, January 2024, the Company recorded in accrued expenses paid \$0.5 million for a sublicense fee owed to Penn related to Sobi obtaining regulatory approval in Japan. Additionally, as of September 30, 2023, in January 2024, the Company recorded in accrued expenses paid \$1.5 million as a result of the achievement of a sales milestone for EMPAVELI and Aspaveli.

As of September 30, 2023 March 31, 2024, the Company has incurred an aggregate royalty expense of \$6.6 9.5 million on sales of EMPAVELI and Aspaveli.

17

[Table of Contents](#)

Beam Research Collaboration

In June 2021, the Company entered into an exclusive five-year research collaboration (the “Beam collaboration agreement”) with Beam Therapeutics, Inc. (“Beam”) focused on the use of Beam’s proprietary base editing technology to discover new treatments for complement-driven diseases. The Company and Beam agreed to collaborate on up to six research programs focused on C3 and other complement targets in the eye, liver and brain. Under the terms of the Beam collaboration agreement, ~~Apellis~~ the Company is responsible for selecting specific genes within the complement system in various organs including the eye, liver and brain (the “Target List”) and providing analytical support while Beam will apply its base editing technology and conduct preclinical research on up to six base editing programs for the Target List. During the first five years of the Beam collaboration agreement, Beam is prohibited from developing on its own or with a third party any base editing therapies associated with the items on the Target List but does not prevent Beam from licensing its intellectual property to a third-party for another purpose outside of the Target List. The Company will have exclusive rights to license each of the six programs and will assume responsibility for subsequent development and commercialization. Beam may elect to enter a 50-50 co-development and U.S. co-commercialization agreement with the Company with respect to any one program licensed under the Beam collaboration agreement and upon such election any license agreement in place at that time, would be terminated.

As part of the Beam collaboration agreement, the Company agreed to pay a \$50.0 million up-front, non-refundable payment to Beam, which the Company paid in July 2021. ~~In June 2022, the~~ The Company paid an additional \$25.0 million which was recorded as a cost on the first anniversary of research the Beam collaboration expense for the year ended December 31, 2021, as it was considered probable of achievement. ~~agreement in June 2022.~~ The Company and Beam are each responsible for their own costs during the research collaboration. If and after the opt-in license rights are exercised for each of the up to six programs, Beam will be eligible to receive development, regulatory and sales milestones from the Company, as well as royalty payments on sales. The Beam collaboration agreement has an initial term of five years and may be extended up to two years on a per year program-by-program basis.

The Company analyzed the Beam collaboration agreement pursuant to ASC 808 to assess whether the agreement involved joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. Since each party is actively participating in this activity and exposed to significant risks and rewards related to the activity through each party’s costs will be accounted for under ASC 808.

Since ASC 808 does not provide recognition guidance, the Company referred to the guidance under FASB ASC Topic 730, *Research and Development* (“ASC 730”), to arrangements involving payments by the Company. ASC 730 requires the Company to recognize research and development costs as expense as incurred since the payment was made for the use of Beam’s intellectual property and research and development services and there is no alternative use.

14.13. Commitments and Contingencies

The Company has certain non-cancelable purchase obligations related to the manufacturing of drug substance and drug product, with Bachem Americas, Inc., under which the Company has agreed to purchase a significant portion of its requirements for the pegcetacoplan drug substance over the ~~next five years~~ initial term of the agreement, which continues until December 31, 2025, and a commercial supply agreement with NOF Corporation, under which the Company has agreed to purchase activated polyethylene glycol

derivative, or PEG, which is a component of pegcetacoplan. Under these agreements, as of **September 30, 2023**, the **March 31, 2024**, the Company is obligated to pay up to **an aggregate of \$113.0** **70.7** million to these vendors. In addition, the Company has other non-cancelable purchase agreements as of **September 30, 2023** **March 31, 2024**, under which it is obligated to pay up to **\$19.1** **19.7** million to vendors.

The Company is a party to a master lease agreement under which the Company leases vehicles with initial terms of 36 months from the date of delivery. If the Company were unable to take delivery of a previously ordered vehicle, the Company may incur nominal fees.

Indemnifications—In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses

21

[Table of Contents](#)

suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred any cost to defend lawsuits or settle claims related to these indemnification provisions.

Legal—During the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. On August 2, 2023, Judith M. Soderberg filed a **complaint** **putative class action** in the United States District Court for the District of Delaware **on behalf of a class of all persons and entities who purchased or otherwise acquired Apellis common stock between January 28, 2021, and July 28, 2023, inclusive**, naming as defendants **against** the Company **President** and **Chief Executive Officer Cedric Francois**, **Chief Financial Officer** and **Treasurer Timothy Sullivan**, **certain current and former Chief Medical Officer Federico Grossi** **executive officers of the Company** (the “Complaint”). The Complaint alleges, among other things, **that the defendants violated Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by misrepresenting and/or omitting certain material facts related to the design of SYFOVRE’s clinical trials and the risks**

18

[Table of Contents](#)

associated with SYFOVRE’s commercial adoption. The Complaint seeks, among other relief, compensatory damages and equitable relief in favor of the alleged class **of plaintiffs** against all defendants, including interest, and reasonable costs and expenses incurred by plaintiffs, including attorneys’ and expert fees.

On October 23, 2023, the Court appointed Ray Peleckas and Michigan Laborers’ Pension Fund together as Co-Lead Plaintiffs and assigned the action the caption **In Apellis Pharmaceuticals, Inc. Securities Litigation, Case 1:23-cv-00834-MN**. The Co-Lead Plaintiffs filed an amended complaint on February 8, 2024 (the “Amended Complaint”). The Amended Complaint is brought on behalf of a class

of all persons and entities who purchased or otherwise acquired Apellis common stock between January 28, 2021 and July 28, 2023, inclusive, names the Company and Cedric Francois, our chief executive officer, as defendants, and makes similar allegations, asserts the same claims and seeks the same relief as the Complaint.

On October 2, 2023, the defendants moved to transfer the action to the United States District Court for the District of Massachusetts.

The Court has not yet ruled on this motion.

The outcome of the matter described above cannot be predicted with certainty, certainty and therefore any loss is neither probable nor reasonably estimable. However, the Company intends to vigorously defend against the litigation.

15.14. Net Loss per Share

Basic and diluted net loss per share is calculated based upon the weighted average number of shares of common stock outstanding during the period. Shares of the Company's common stock underlying pre-funded warrants are included in the calculation of basic and diluted earnings per share. Since the Company was in a loss position for all periods presented, basic net loss per common share is the same as diluted net loss per common share for all periods presented as the inclusion of all potential common shares outstanding would have been anti-dilutive. Convertible notes and shares outstanding presented below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, as their effect is anti-dilutive (in thousands):

	As of September 30,	
	2023	2022
Convertible notes	2,379	2,379
Common stock options	9,738	12,511
Restricted stock units	4,449	3,568
Total	16,566	18,458

	As of March 31,	
	2024	2023
Convertible notes	2,379	2,379
Common stock options	8,576	12,002
Restricted stock units	4,587	4,764
Total	15,542	19,145

2219

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes for the year ended December 31, 2022 December 31, 2023 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 21, 2023 February 27, 2024, [, as amended by Amendment No. 1 thereto filed with the Securities and Exchange Commission on February 29, 2024,] which we refer to as the 2022 2023 Annual Report on Form 10-K. 10-K

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Please also refer to those factors described in "Part I, Item 1A. Risk Factors" of our 2022 2023 Annual Report on Form 10-K and "Part II, Item 1A. Risk Factors" of this Quarterly Report on Form 10-Q for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements.

Overview

We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control diseases with high unmet need and that are driven by excessive complement activation.

In February 2023, the U.S. Food and Drug Administration, or the FDA, approved SYFOVRE SYFOVRE® (pegcetacoplan injection), the first approved treatment for geographic atrophy secondary to age-related macular degeneration, or GA. We believe SYFOVRE has the potential to be a best-in-class treatment for patients with GA, a disease that affects more than one million people in the United States and five million people worldwide. We launched SYFOVRE in the United States in March 2023. For the three and nine months ended September 30, 2023, March 31, 2024 and 2023 we generated \$75.3 million \$137.5 million and \$161.0 million \$18.4 million, respectively, in U.S. net product revenue from sales of SYFOVRE.

In December 2022, we also submitted a Our marketing authorization application, or MAA, to the European Medicines Agency, or EMA, for intravitreal pegcetacoplan for the treatment of GA. The EMA subsequently provided MAA validation and the application GA is under review. In April 2024, the EMA reset the MAA review to day 180, the last phase of the initial assessment, and we expect now anticipate an opinion from the Committee for Medicinal Products for Human Use, or CHMP, no later than July 2024. The EMA's decision was strictly procedural and in response to a decision in early 2024. Additionally, we received validation judgment by the Court of our Justice of the European Union regarding the organization of the EMA's expert groups, and was not related to the pegcetacoplan data package. We have submitted marketing applications by to regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for SYFOVRE for the treatment of GA, and expect decisions which are each under review by local the applicable regulatory authorities in the first half of 2024. authorities. We have exclusive, worldwide commercialization rights for intravitreal pegcetacoplan.

In July 2023, we disclosed data from GALE, our long-term extension trial As of SYFOVRE, which demonstrated increasing treatment effects over 30 months in patients with GA. The safety profile of SYFOVRE in the GALE study continued to be consistent with previously reported Phase 3 data. We expect to present additional 36-month data from GALE at the American Academy of Ophthalmology Annual Meeting in November 2023.

In July 2023 we disclosed that we had received reports of a small number of events of retinal vasculitis following SYFOVRE treatment. We provided additional disclosures on these events in August and October. March 31, 2024, Based upon our review of these events after the distribution of more than 100,000 vials of SYFOVRE after its commercial launch, we estimate that the rate of incidence of retinal vasculitis is following SYFOVRE treatment remains rare at approximately 0.01%per injection. We believe that these reports had an impact on our sales the events of retinal vasculitis predominantly occur in the first injection of SYFOVRE, during the three and nine months ended September 30, 2023, with an estimated rate at first injection at approximately 1 in 4,000.

The On October 1, 2023, the U.S. Centers for Medicare & Medicaid Services assigned a permanent and product-specific J-code for SYFOVRE, which became effective on October 1, 2023, the same day. J-codes are permanent reimbursement codes used by government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a healthcare professional.

In May 2021, the FDA approved EMPAVELI (pegcetacoplan) (systemic pegcetacoplan), the first targeted C3 therapy, for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. EMPAVELI is approved PNH, for use in adults with PNH and can be used by patients who are either treatment-naïve or who are switching from C5 inhibitors eculizumab or ravulizumab. We believe that EMPAVELI has the potential to elevate

23

[Table of Contents](#)

the standard of care in PNH and are seeking to establish EMPAVELI as the preferred first-line treatment for patients. In the United States, there are approximately 1,500 patients with PNH currently being treated with C5 inhibitors and another 150 patients who are expected to be newly diagnosed each year. In October 2023, the FDA approved the EMPAVELI injector, a compact, single-use, on-body device designed to enhance self-administration of EMPAVELI. For the three and nine months ended September 30, 2023, March 31, 2024 and 2023, we generated \$23.9 million \$25.6 million and \$66.6 million \$20.4 million, respectively, in net product revenue from sales of EMPAVELI. For the three and nine months ended September 30, 2022, we generated \$17.7 million and \$45.4 million, respectively, in U.S. net product revenue from sales of EMPAVELI.

20

[Table of Contents](#)

In December 2021, the European Commission, or the EC, Systemic pegcetacoplan has been approved Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. To date, systemic pegcetacoplan has also been approved for in the treatment of PNH in European Union, Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan It is currently marketed under the trade name EMPAVELI in the United

States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom. Under our collaboration and license agreement, or the Sobi collaboration agreement, with Swedish Orphan Biovitrum AB (Publ), or Sobi, Sobi has global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan and initiated the commercial launch of EMPAVELI/Aspaveli in jurisdictions outside of the United States, during the first quarter of 2022. We and we have commercialization rights for systemic pegcetacoplan in the United States.

We believe that inhibition of the complement system by targeting C3 may enable a broad range of therapeutic approaches, and that pegcetacoplan has the potential to address the limitations of existing treatment options or provide a treatment option in indications where there currently are none. We are leading the development of systemic pegcetacoplan in C3 glomerulopathy, or C3G, and primary immune complex membranoproliferative glomerulonephritis, or primary IC-MPGN, in nephrology. In October 2023, we announced positive results from the Phase 2 NOBLE trial investigating pegcetacoplan for the treatment of post-transplant recurrence of primary IC-MPGN and C3G. The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated nephrology under our collaboration with pegcetacoplan. Specifically, in at 12 weeks, 80% of patients showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline and 40% of patients showed zero staining intensity, indicating that C3c deposits were cleared. Patients also showed improvements across key clinical measures, including a mean reduction in proteinuria, and stabilized kidney function. There were no discontinuations due to treatment-emergent adverse events. Apellis plans Sobi. We plan to report top-line data from the ongoing Phase 3 VALIANT trial investigating systemic pegcetacoplan in adolescent and adult patients with native and post-transplant recurrence IC-MPGN and C3G in the third quarter of 2024.

mid-2024. Under our collaboration with Sobi, we are co-developing Sobi is leading the development of systemic pegcetacoplan for cold agglutinin disease, or CAD, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy, or HSCT-TMA, in hematology. We are also evaluating the administration of systemic pegcetacoplan as a novel approach to enabling xenotransplantation procedures and adeno associated virus, or AAV, vector administration for gene therapies.

In May 2023, January 2024, together with Sobi, we and Sobi announced that discontinued the CASCADE Phase 2 MERIDIAN study 3 trial evaluating systemic pegcetacoplan for amyotrophic lateral sclerosis, in patients with cold agglutinin disease, or ALS, did not meet its primary or key secondary endpoints. Based on this lack of efficacy, we and Sobi discontinued development of systemic pegcetacoplan for ALS. Systemic pegcetacoplan was well tolerated CAD, due to the decreased medical need in the trial, CAD and the safety data were consistent with limited number of patients eligible for the established safety profile. In August 2023, in connection with our corporate restructuring, we announced that we do not plan to initiate any new clinical development programs with systemic pegcetacoplan. CASCADE trial.

Lastly, we We are developing additional product candidates with other routes of administration and plan to advance these product candidates into clinical development in 2023 administration. These candidates include an oral alternative pathway inhibitor for certain renal conditions. We submitted an investigational new drug application, or IND, for APL-3007, a small interfering RNA, or siRNA, in March 2023 and dosed the first subject which is in a Phase 1 clinical trial in June 2023. healthy volunteers, for which we expect to report topline data later this year, as well as an oral complement inhibitor in preclinical development. Furthermore, we are collaborating with Beam Therapeutics, Inc., or Beam, on up to six research programs focused on C3 and other complement targets in the eye, liver and brain, using Beam's proprietary base editing technology to discover new treatments for complement-driven diseases. In August 2023, we announced our intent to prioritize research initiatives in retinal and central nervous system diseases and deprioritize certain development initiatives, including APL-1030 and APL-2006.

Since our commencement of operations in May 2010, we have devoted substantially all of our resources to developing our proprietary technology, developing product candidates, undertaking preclinical studies and conducting clinical trials for pegcetacoplan, building our intellectual property portfolio, organizing and staffing our company, business planning, raising capital, preparing for and executing the commercial launch of our products and providing general and administrative support for these operations.

In August 2023,

To date, we committed to a workforce reduction of approximately 225 employees, or approximately 25% have financed our operations primarily through \$1.9 billion in net proceeds from public offerings of our then current workforce. Pursuant common stock and pre-funded warrants to purchase common stock, \$535.8 million in net proceeds from offerings of Convertible Notes, a \$250.0 million up-front payment and \$65.0 million development reimbursement payments from Sobi pursuant to the restructuring, we plan to continue to support Sobi collaboration agreement, \$112.6 million in proceeds from the U.S. commercial launch private placement of SYFOVRE and are preparing for potential ex-U.S. launches (ii) plan to reduce EMPAVELI expenses through a more focused commercial and medical PNH organization and (iii) intends to prioritize research initiatives in retina and central nervous system diseases and plan to continue our collaboration with Beam. We expect that the corporate restructuring and associated reduction in workforce will result in total cost savings of up to \$300 million through 2024, which includes more than \$70 million in expected net costs savings related to the reduction in workforce and up to \$230 million related to elimination of planned external expenses. Our workforce reduction was substantially completed in the three months ended September 30, 2023. As a result shares of our workforce reduction, convertible preferred stock prior to our initial public offering, or IPO, \$140.0 million under the SFJ agreement, \$20.0 million in proceeds from borrowings under a term loan facility with Silicon Valley Bank, and \$7.0 million in proceeds from our issuance and sale of a promissory note. We have repaid the term loan facility and the promissory note in full, and we incurred exchanged \$425.4 million and converted \$0.7 million of aggregate principal amount of our Convertible Notes for shares of our common stock.

24

[Table of Contents](#)

approximately \$10.0 million in costs in the three months ended September 30, 2023, substantially all of which were cash expenditures. Any additional costs we may incur during the remainder of 2023 are not expected to be material. As of September 30, 2023, we had cash and cash equivalents of \$452.4 million. We believe that our cash and cash equivalents, along with cash anticipated to be generated from sales of EMPAVELI and SYFOVRE and the remaining committed development reimbursement payment from Sobi, will be sufficient to fund our current operations into at least the second quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In particular, we are assessing the impact of the reported safety events with SYFOVRE on our assumptions regarding future revenues. For additional information see "Liquidity and Capital Resources" elsewhere in this Quarterly Report on Form 10-Q.

Since the launch of EMPAVELI in May 2021 and SYFOVRE in March 2023, through September 30, 2023 we have generated \$307.8 million of net product revenue from sales of EMPAVELI and SYFOVRE. We have incurred significant annual net operating losses in every year since our inception and we expect to continue to incur net operating losses for at least this year and next year. Our net losses were \$140.2 million \$66.4 million and \$191.3 million \$177.8 million for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively, and \$440.1 million and \$486.2 million for the nine months ended September 30, 2023 and 2022, 2023, respectively. As of September 30, 2023 March 31, 2024, we had an accumulated deficit of \$2.7 billion \$2.9 billion.

Our net losses operating results may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses we will increase significantly particularly as we continue to incur significant commercialization expenses related to sales, marketing, medical affairs, manufacturing, distribution and other commercial infrastructure associated with the commercialization of EMPAVELI for the treatment of PNH and the commercialization of SYFOVRE for the treatment of GA. In addition, we expect our to continue to incur these expenses to increase if and as we continue to develop and conduct our ongoing and planned clinical trials of pegcetacoplan and our other product candidates; initiate and continue research and preclinical and clinical development efforts for any future product candidates; seek to identify and develop additional product candidates for complement-dependent diseases; seek regulatory and

marketing approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to commercialize any additional products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain additional personnel, such as clinical, quality control, regulatory and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and add equipment and physical infrastructure to support our research and development programs and commercialization.

[Table of Contents](#)

SFJ Agreement

On February 28, 2019, we entered into a development funding agreement, which we refer to as the SFJ agreement, with SFJ Pharmaceuticals Group, or SFJ, under which SFJ agreed to provide funding to us to support the development of systemic pegcetacoplan for the treatment of patients with PNH. Pursuant to the agreement, SFJ paid us \$60.0 million following the signing of the agreement and agreed to pay us up to an additional \$60.0 million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to our Phase 3 program for pegcetacoplan in PNH and subject to our having cash resources at the time sufficient to fund at least 10 months of our operations.

On June 7, 2019,

In June 2019 we amended the SFJ agreement which we refer to as the SFJ amendment. Under the SFJ amendment, SFJ agreed to make include an additional \$20.0 million \$20 million funding payment to payment. SFJ paid us to support the development of systemic pegcetacoplan for the treatment of patients with PNH.

On June 27, 2019, we received \$40.0 million from SFJ, consisting of \$20.0 million as the first installment of the additional \$60.0 million upon the achievement of a milestone and the \$20.0 million payable \$80.0 million under the amended SFJ amendment.

In September agreement between June 2019 we received \$20.0 million from SFJ, as the second installment of the additional \$60.0 million due to the achievement of a milestone and in January 2020 received the remaining \$20.0 million installment of the additional \$60.0 million upon the announcement of the results of the PEGASUS phase 3 trial. 2020.

Under the SFJ agreement, following regulatory approvals by the FDA and the EMA European Commission, or the EC, for the use of systemic pegcetacoplan as a treatment for PNH, we paid SFJ \$4.0 million in 2021 in connection with the FDA approval in May 2021 and \$5.0 million in January 2022 in connection with the EMA EC approval in December 2021. In addition, we paid \$11.5 million in connection with the one-year anniversary of the FDA approval in May 2022 and \$18.0 million in connection with the one-year anniversary of the EMA EC approval in December 2022 and \$24.5 million in connection with the two year two-year anniversary of FDA approval in May 2023 and \$31.0 million in connection with the two-year anniversary of EC approval in December 2023. We are obligated to pay SFJ an additional \$31.0 million during 2023, with \$366.0 million in additional payments due on each anniversary of

FDA and **EMA** EC regulatory approval through **2027**. 2027 with \$37.5 million due in May 2024 and \$61.3 million due in December 2024.

Convertible Notes

25

[Table of Contents](#)

On September 16, 2019, we completed a private offering of convertible notes, or the 2019 Convertible Notes, with an aggregate principal amount of \$220.0 million issued pursuant to an indenture, or the Indenture, with U.S. Bank National Association, as trustee. The net proceeds from the sale of the 2019 Convertible Notes were approximately \$212.9 million after deducting the initial purchasers' discounts and commissions of \$6.6 million and offering expenses of \$0.5 million. We used \$28.4 million of the net proceeds from the sale of the 2019 Convertible Notes to pay the cost of the capped call transactions in September 2019 described below.

On **May 12, 2020**, **May 12, 2020**, we issued convertible notes, or the 2020 Convertible Notes, with an aggregate principal amount of \$300.0 million. The net proceeds from the sale of the 2020 Convertible Notes were approximately \$322.9 million after deducting the purchasers' discounts and commission of \$5.7 million and offering expenses of \$0.3 million. We used \$43.1 million of the net proceeds from the sale to pay the cost of the additional capped call transactions in May 2020 described below.

The 2019 **Convertible** **Convertible** Notes and the 2020 Convertible Notes are referred to together as the Convertible Notes. The Convertible Notes are our senior unsecured obligations and bear interest at a rate of 3.5% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2020. The Convertible Notes will mature on September 15, 2026, unless converted earlier, redeemed or repurchased in accordance with their terms.

The Convertible Notes are convertible into shares of our common stock at an initial conversion rate of 25.3405 shares per \$1,000 principal amount of notes (equivalent to an initial conversion price of approximately \$39.4625 per share of common stock). The conversion rate is subject to customary anti-dilution adjustments. In addition, following certain events that occur prior to the maturity date or if we deliver a notice of redemption, we will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or a notice of redemption, as the case may be, in certain circumstances as provided in the Indenture.

Prior to March 15, 2026, the Convertible Notes are convertible only under the following circumstances:

- during any calendar quarter, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
- during the five business day period after any five consecutive trading day period in which the trading price per \$1,000 principal amount of the Convertible Notes for each such trading day was less than 98% of the product of the last reported sale price of common stock and the conversion rate on each such trading day;

22

[Table of Contents](#)

- if we call any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled

trading day immediately preceding the redemption date; or upon the occurrence of corporate events specified in the Indenture. On or after March 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date of the Convertible Notes, holders may convert the Convertible Notes at any time regardless of the foregoing circumstances. Upon conversion of the Convertible Notes, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of common stock, at our election.

Prior to September 20, 2023, we could not redeem the Convertible Notes. From and after As of September 20, 2023, we may redeem for cash all or a portion of the Convertible Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide a notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we call any Convertible Notes for redemption, it will constitute a "make-whole fundamental change" with respect to such Convertible Notes, in which case the conversion rate applicable to the conversion of such Notes, if converted in connection with the redemption, will be increased in certain circumstances. We have not called for redemption or redeemed any of the Convertible Notes as of September 30, 2023 March 31, 2024.

If we undergo a "fundamental change," as defined in the Indenture, prior to maturity, subject to certain conditions, holders may require us to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% 100 % of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

Table of Contents

We used an effective interest rate of 10.5% to determine the liability component of the Convertible Notes. This resulted in the recognition of \$145.1 million and \$204.5 million as the liability component of the 2019 and 2020 Convertible Notes, respectively, and the recognition of the residual amount of \$74.9 million and \$95.5 million as the debt discount with a corresponding increase to additional paid in capital for the equity component of the 2019 and 2020 Convertible Notes, respectively. The 2020 Convertible Notes aggregate debt issuance costs of \$6.0 million were allocated to the liability and equity components in the amounts of \$3.7 and \$2.3 million, respectively. The 2019 Convertible Notes aggregate debt issuance costs of \$7.1 million were allocated to the liability and equity components in the amounts of \$4.7 million and \$2.4 million, respectively.

Effective January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method. Upon adoption, we increased net debt and reduced net equity by \$149.7 million. The \$149.7 million consisted of several items. The first item is the reclassification from equity to debt of the residual amounts originally identified as the equity components of the 2019 and 2020 Convertible Notes of \$74.9 million and \$95.5 million, respectively. The equity component reclassification was offset by the adjustment to retained earnings for the reversal of previous non-cash interest expense recorded for the amortization of the equity components of \$17.1 million. The second item is the reclassification from equity to debt of the debt issuance costs originally allocated to equity for the 2019 and 2020 Convertible Notes of \$2.4 million and \$2.3 million, respectively. The debt issuance costs reclassification was offset by the adjustment to retained earnings for previous amortization of the debt issuance costs recorded of \$1.1 million.

In January 2021, July 2021 and July 2022, we entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of our the 2019 Convertible Notes and 2020 Convertible Notes. Under the terms of these exchange agreements, in January 2021, July 2021 and July 2022, the holders exchanged approximately \$126.1 million of 2019 Convertible Notes, \$201.1 million of 2019 Convertible Notes and 2020 Convertible Notes, and \$98.1 million of 2020 Convertible Notes,

respectively, in aggregate principal amount held by them for an aggregate of 3,906,869 shares, 5,992,217 shares and 3,027,018 shares, respectively, of common stock we issued. In accordance with FASB ASC Topic 470-20, "Debt – Debt with Conversion and Other Options," or ASC 470-20, we accounted for the exchange as an induced conversion based on the short period of time the conversion offer was open and the substantive conversion feature offer. We accounted for the conversion of the debt as an inducement by expensing the fair value of the shares that were issued in excess of the original terms of the Convertible Notes.

As a result of the January 2021 exchange transactions, we reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$122.8 million, consisting of the par value of the 2019 Convertible Notes exchanged of \$126.1 million less the \$3.3 million of remaining debt issuance costs associated with the exchanged notes. We also increased shares outstanding by 3,906,869 shares consisting of 3,196,172 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 710,697 shares. Additionally, we issued 69,491 shares as settlement of debt issuance costs paid to our financial advisor in connection with the exchange transaction. For the three months ended March 31, 2021, we recorded a loss on conversion of debt of \$39.5 million comprised of \$36.4 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$3.1 million for the value of the 69,491 shares issued in payment of issuance costs at their then fair value. Upon exchange of the 2019 Convertible Notes, the holders forfeited accrued interest through the date of the exchange of \$1.7 million, which we charged to interest expense and to equity.

As a result of the July 2021 exchange transactions, we reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$197.0 million, consisting of the par value of the Convertible Notes exchanged of \$201.1 million less the \$4.1 million of remaining debt issuance costs associated with the exchanged notes. We also increased shares outstanding by 5,992,217 shares consisting of 5,097,166 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 895,051 shares. Additionally, we issued 78,419 shares as settlement of issuance costs paid to our financial advisor in connection with the exchange transaction. For the three months ended September 30, 2021, we recorded a loss on conversion of debt of \$61.1 million comprised of \$55.9 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$5.2 million for the value of the 78,419 shares issued in payment of issuance costs at their then fair value. Upon exchange of the Convertible Notes, the holders forfeited accrued interest through the date of the exchange of \$2.5 million, which we charged to interest expense and to equity.

As a result of the July 2022 exchange transactions, we reduced net debt outstanding and increased net equity on the consolidated balance sheet by \$96.8 million, consisting of the par value of the Convertible Notes exchanged of \$98.1 million less the \$1.3 million of remaining debt issuance costs associated with the exchanged notes. We also increased shares outstanding by 3,027,018 shares consisting of 2,485,548 shares issued at the initial conversion rate in the Indenture of 25.3405 plus an additional 541,470 shares. Additionally, we issued 46,132 shares as settlement of issuance costs paid to our financial advisor in connection with the exchange transaction. For the three months ended September 30, 2022, we recorded a loss on conversion of debt of \$32.9 million comprised of \$30.4 million related to the value of the shares issued in excess of the original conversion terms at the fair market value and \$2.5 million for the value of the 46,132 shares.

A The conditional conversion feature of the Convertible Notes was triggered as of June 30, 2021 December 31, 2023, and as a result the Convertible Notes were convertible at the option of the holders until September 30, 2021 March 31, 2024. During this period, certain holders of the Convertible Notes

The conditional conversion feature of the Convertible Notes was again triggered as of March 31, 2023 and as a result the No Convertible Notes were convertible at the option of the holders until June 30, 2023. During converted during this period, no Convertible Notes were converted. period.

The conditional conversion feature of the Convertible Notes was again triggered as of June 30, 2023 March 31, 2024, and as a result the Convertible Notes became are convertible at the option of the holders until September 30, 2023 June 30, 2024. During this period, no Convertible Notes were converted.

As of September 30, 2023 March 31, 2024, we held in treasury Convertible Notes in principal amount of \$425.4 million which notes had not been cancelled.

Collaboration Agreement with Sobi

On October 27, 2020, we entered into the Sobi collaboration agreement, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration, collectively referred to as the licensed products. We granted Sobi an exclusive (subject to certain rights retained by us), sublicensable license of certain patent rights and know-how to develop and commercialize licensed products in all countries outside of the United States. We retained the right to commercialize licensed products in the United States, and, subject to specified limitations, to develop licensed products worldwide for commercialization in the United States. Under the Sobi collaboration agreement, Sobi made an upfront payment of \$250.0 million in November 2020, and agreed to pay up to an aggregate of \$915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, including a \$50.0 million milestone which would be payable following the first regulatory and reimbursement approval of systemic pegcetacoplan in any major European country, and to reimburse us for up to \$80.0 million in development costs. Following our In January 2021 we received a \$25.0 million development reimbursement payment from Sobi and Sobi's in January 2022 and 2023, we received a \$20.0 million development reimbursement payment from Sobi. In January 2024, we waived the remaining reimbursement payment of \$15.0 million in connection with the decision to discontinue the CAD program.

23

Table of Contents

In May 2023, we and Sobi announced that the Phase 2 MERIDIAN study evaluating systemic pegcetacoplan for amyotrophic lateral sclerosis, or ALS, did not meet its primary or key secondary endpoints. Based on this lack of efficacy, we and Sobi discontinued development of systemic pegcetacoplan for ALS, we will not achieve the milestones related to that indication, which represent \$120.0 million of the \$915.0 million aggregate amount. In January 2021, January 2022 and January 2023, we received a \$25.0 million, \$20.0 million and \$20.0 million development reimbursement payment from Sobi, respectively. The remaining \$15.0 million is due from Sobi in January 2024. ALS.

We received The EC approval of approved systemic Aspaveli (pegcetacoplan) for the treatment of adults with PNH in December 2021. In March 2022, we earned a \$50.0 million payment from Sobi related to the first regulatory and reimbursement milestone in Europe.

We considered the reimbursement approval to be probable at December 31, 2021, and recorded revenue at that time. In September 2023, Europe, which we earned a \$5.0 million payment from Sobi related to the first regulatory and reimbursement milestone in Japan. We received the \$50.0 million payment in April 2022 and \$5.0 million payment in October 2023 for the achievement of a regulatory development milestone in Europe and Japan, respectively. We received the \$50.0 million payment in April 2022 and \$5.0 million in October 2023 for the achievement of a regulatory development milestone in Japan. 2022. We are also entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales of licensed products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable licensed product, in each case on a licensed product-by-licensed product and country-by-country basis. We remain responsible for our license fee obligations (including royalty obligations) to the University of Pennsylvania and for our payment obligations to SFJ.

Financial Operations Overview

Revenue

Our revenues consist of product sales of EMPAVELI and SYFOVRE, and revenues derived from our collaboration agreement with Sobi.

Revenue is recognized when, or as, we satisfy a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. For performance obligations that are satisfied over time, we recognize revenue using an input or output measure of progress that best depicts the satisfaction of the relevant performance obligation.

Product Revenues

Product revenue is derived from our sales of our commercial products, EMPAVELI and SYFOVRE, in the United States.

28

[Table of Contents](#)

Licensing and Other Revenue

Licensing and other revenue is derived from our collaboration agreement with Sobi concerning the development and commercialization of pegcetacoplan and specified other compstatin analogues or derivatives for use systemically or for local non-ophthalmic administration.

Cost of Sales

Cost of sales consists primarily of costs associated with the manufacturing of EMPAVELI and SYFOVRE, costs associated with revenue from our collaboration agreement with Sobi, royalties owed to our licensor for such sales, and certain period costs.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:

- employee-related expenses including salaries, bonuses, benefits and share-based compensation expense related to individuals performing research and development activities;

- expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials and research and development activities on our behalf, and contract manufacturing organizations that manufacture quantities of drug supplies for both our preclinical studies and clinical trials;
- the cost of consultants, including share-based compensation expense; and
- various other expenses incident to the management of our preclinical studies and clinical trials.

Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the

[Table of Contents](#)

related goods are delivered or the services are performed. We have not provided program costs since inception because historically we have not tracked or recorded our research and development expenses on a **program-by-program** **program-by-program** basis from **inception**

The successful development of our product candidates in clinical development is highly uncertain. Accordingly, at this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be necessary to complete the remainder of the clinical development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from pegcetacoplan in other jurisdictions and indications or any other potential product candidates. This is due to the numerous risks and uncertainties associated with developing therapeutics, including the uncertainties of:

- establishing an appropriate safety profile in preclinical studies;
- successful enrollment in, and completion of clinical trials;
- receipt of marketing approvals from applicable regulatory authorities;
- establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
- obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
- launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and
- an acceptable safety profile of the products following approval.

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur research and development costs to increase for the foreseeable future as our product candidate development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many

of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.

[Table of Contents](#)

Selling, General and Administrative Expenses

General

Selling, general and administrative expenses consist primarily of employee-related expenses costs associated with the commercialization of approved products and general and administrative costs to support operations, including salaries, bonuses, benefits and share-based compensation. In addition, certain Selling expenses include product marketing, sales operations costs, incurred for medical affairs, regulatory, quality, drug safety, and pharmacovigilance activities other costs incurred to support our commercial products are classified as general sales efforts. General and administrative expenses include corporate support functions such as executive management, finance and accounting, business development, legal, human resources, information technology, and associated external costs to appropriately reflect the nature of the expenditure incurred. support those functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.

We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development commercial activities for our approved products, potential commercialization of our product candidates and costs of operating as a public company.

Critical Accounting Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reported periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to product revenue, licensing revenue, costs of research collaboration arrangements, inventory, accrued research and development expenses, convertible notes, capped call transactions and the development derivative and development liability, which we described in our 2022 2023 Annual Report on Form 10-K. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

[Table of Contents](#)

Our significant accounting policies are described in Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q and in Part I, Item 7, "Critical Accounting Policies and Estimates" in our 2022 2023 Annual Report on Form 10-K. There have been no changes to our critical accounting policies and estimates that we identified in since our 2022 2023 Annual Report on Form 10-K.

Results of Operations

Three Months Ended September 30, 2023 March 31, 2024 and 2022 2023 (in thousands, except percentages)

	For the Three Months Ended		Chang	Chan	For the Three Months Ended March		Change	Change
	September 30,				2024	2023		
	2023	2022	\$	%	2024	2023	\$	%
Revenue:								
Product revenue, net	\$ 99,182	\$ 17,676	\$ 06	1%	\$ 163,075	\$ 38,800	\$ 124,275	320%
Licensing and other revenue	11,217	4,380	6,83	15%	9,250	6,046	3,204	53%
Total revenue:	110,399	22,056	88,3	40%	172,325	44,846	127,479	284%
Operating expenses:								
Cost of sales	22,410	1,381	21,0	1,5	20,209	7,809	12,400	159%
Research and development	79,421	95,207	(15,		84,701	110,027	(25,326)	(23%)
General and administrative	145,648	78,406	67,2					
Selling, general and administrative			42	86%	129,505	102,093	27,412	27%
Total operating expenses:	247,479	174,994	72,4		234,415	219,929	14,486	7%
Net operating loss	(137,08	(152,93	85	41%	(62,090)	(175,083)	112,993	(65%)
Loss on conversion of debt	—	(32,890)	32,8	(10				
Interest income	4,989	2,809	90	0%)	3,303	5,393	(2,090)	(39%)
Interest expense	(7,310)	(7,903)	2,18		(6,967)	(7,529)	562	(7%)
Other (expense)/income, net	(603)	99	(702)	(70	(499)	(277)	(222)	80%
Net loss before taxes	(140,00	(190,82	50,8		(66,253)	(177,496)	111,243	(63%)

Income tax expense	233	446	(213)	(48 %)	170	282	(112)	(40 %)
	(140,23)	(191,26)	51,0					
Net loss	\$ 7	\$ 9)	\$ 32	(27 %)	\$ (66,423)	\$ (177,778)	\$ 111,355	(63 %)

Product Revenue, Net

Our product revenue, net is derived from EMPAVELI sales in the United States which was launched in May 2021 and SYFOVRE sales in the United States. States which was launched in March 2023. We recognized \$99.2 million \$163.1 million and \$17.7 million \$38.8 million of net product revenue for the three months ended September 30, 2023 March 31, 2024 and 2022,

30

[Table of Contents](#)

2023, respectively. The net product revenue of \$99.2 million \$163.1 million for the three months ended September 30, 2023 March 31, 2024, consists of \$23.9 million \$25.6 million in net product revenue from sales of EMPAVELI and \$75.3 million \$137.5 million in net product revenue from sales of SYFOVRE. The net product revenue of \$38.8 million for the three months ended March 31, 2023, consists of \$20.4 million in net product revenue from sales of EMPAVELI and \$18.4 million in net product revenue from sales of SYFOVRE.

Licensing and Other Revenue

Licensing and other revenue of \$11.2 million \$9.3 million for the three months ended September 30, 2023 March 31, 2024 consisted of \$3.5 million in revenue from product supplied to Sobi, \$2.7 million in royalty revenue from Sobi and \$5.0 million from collaboration with Sobi. Licensing and other revenue of \$4.4 million for the three months ended September 30, 2022 consisted of \$3.6 million \$4.8 million in revenue from product supplied to Sobi and \$0.8 million \$4.5 million in royalty revenue from Sobi. Licensing and other revenue of \$6.0 million for the three months ended March 31, 2023 consisted of \$4.5 million in revenue from product supplied to Sobi and \$1.6 million in royalty revenue from Sobi.

Cost of Sales

Cost of sales was \$22.4 million \$20.2 million for the three months ended September 30, 2023 March 31, 2024 and \$1.4 million \$7.8 million for the three months ended September 30, 2022 March 31, 2023. The increase in cost of sales was primarily driven by a \$10.1 million \$1.9 million increase due to increased product higher volume from commercial sales and product provided under our patient assistance programs, a \$0.3 million increase from cost of supply provided under the Sobi collaboration agreement, a \$2.6 million \$4.7 million increase in royalty expense, a \$6.5 million increase due to the achievement of various sales-based milestones, a \$0.5 million increase due to a sublicense fee, and a \$1.0 million \$5.4 million increase in expenses incurred related to excess or obsolete inventory.

In addition, prior to receiving FDA approval for EMPAVELI and SYFOVRE, the costs associated with the manufacturing of EMPAVELI and SYFOVRE inventory were expensed as incurred as research and development expense. This resulted in inventory being sold did not materially impact cost of sales for the three months ended September 30, 2023 March 31, 2024 and 2022 for which a portion of the costs had been previously expensed prior to FDA approval. 2023. We expect this to may continue to impact the cost of sales as

26

[Table of Contents](#)

the remaining pre-FDA approval inventory is sold to customers. As of March 31, 2024, the remaining pre-FDA approved inventory was \$19.4 million, which primarily consisted of raw materials.

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the three months ended **September 30, 2023** **March 31, 2024** and **2022** (in thousands, except percentages):

	For the Three Months Ended				Change	Change		
	September 30,							
	2023	2022	\$	%				
Clinical trial costs	\$ 20,594	\$ 19,495	\$ 1,099	6 %				
Compensation and related personnel costs	34,046	40,731	(6,685)	(16 %)				
Contract manufacturing	9,720	11,317	(1,597)	(14 %)				
Research/innovation costs	6,291	6,228	63	1 %				
Other development costs	4,964	13,573	(8,609)	(63 %)				
Pre-clinical study expenses	2,511	2,428	83	3 %				
Device development expenses	1,295	1,435	(140)	(10 %)				
Total research and development expenses	\$ 79,421	\$ 95,207	\$ (15,786)	(17 %)				

(In thousands)	For the Three Months Ended March 31,		Change	Change
	2024	2023		
Program-specific external costs:				
PNH	\$ 4,397	\$ 5,086	(689)	(14 %)
IC-MPGN & C3G	9,230	8,464	766	9 %
ALS	358	6,341	(5,983)	(94 %)
CAD	16,228	2,279	13,949	612 %
HSCT-TMA	564	1,712	(1,148)	(67 %)
GA	9,975	15,559	(5,584)	(36 %)
Other development and discovery programs	9,930	16,414	(6,484)	(40 %)
Total program-specific costs	50,682	55,855	(5,173)	(9 %)
Unallocated external costs				
Non-program specific external costs	312	2,905	(2,593)	(89 %)
Total unallocated external costs	312	2,905	(2,593)	(89 %)
Unallocated internal costs				
Compensation and related personnel costs	32,546	50,055	(17,509)	(35 %)

Other expenses	1,161	1,212	(51)	(4 %)
Total unallocated internal costs	33,707	51,267	(17,560)	(34 %)
Total research and development costs	\$ 84,701	\$ 110,027	\$ (25,326)	(23 %)

Research and development expenses decreased by \$15.8 million \$25.3 million to \$79.4 million \$84.7 million for the three months ended September 30, 2023 March 31, 2024 from \$95.2 million \$110.0 million for the three months ended September 30, 2022 March 31, 2023, a decrease of 17% 23%. The decrease in research and development expenses was primarily attributable to a \$5.2 million decrease of \$6.7 million in personnel related program specific external costs, a \$2.6 million decrease in non-program specific external costs, and a \$17.5 million decrease in compensation and related personnel costs.

The decrease in our program-specific external costs of \$1.6 million \$5.2 million was driven by a \$5.6 million decrease in contract manufacturing expenses GA costs which largely reflects the impact of the approval of SYFOVRE in February 2023, a \$6.0 million decrease in ALS costs due primarily to the timing discontinuation of drug supply the Phase 2 MERIDIAN study, and analytical activity, a \$6.5 million decrease of \$8.6 million in other development and discovery program costs. The decrease was These decreases were partially offset by a \$1.1 million increase in a clinical trial costs due \$15.0 million one-time expense related to the completion discontinuation of our Phase 3 DERBY and OAKS trials. the CAD program.

General The decrease in compensation and Administrative Expenses

General and administrative expenses increased related personnel costs was driven by \$67.2 million to \$145.7 million for the three months ended September 30, 2023, from \$78.4 million for the three months ended September 30, 2022, an increase of 86%. The increase was primarily attributable to an increase in personnel related costs of \$17.1 million including termination benefits charges in connection with the corporate restructuring plan, an increase in professional and consulting fees and general commercial preparation activities of \$45.8 million, an increase in travel related expenses of \$0.9 million, higher office costs of \$3.6 million. The increase was partially offset by lower insurance costs of \$0.1 million and lower director stock option compensation of \$0.1 million . The increase in personnel related costs of \$17.1 million consisted of a \$17.2 million increase \$15.8 million decrease in salaries and benefits primarily due to having more employees lower headcount compared to the prior year and a \$1.7 million decrease in the three months ended September 30, 2023, partially offset by a decrease of \$0.1 million related to stock compensation expense associated with the grant of stock options and restricted stock units to employees. The increase in other professional Lower headcount was driven by the reclassification of certain employee costs to selling, general and consulting fees and administrative expenses.

31

[Table of Contents](#)

general commercial preparation activities of \$45.8 million consisted primarily of higher commercialization related activity of \$44.6 million, and an increase in general professional fees of \$1.2 million.

Loss on Conversion of Debt Selling, General and Administrative Expenses

Loss on conversion of debt was \$32.9 million Selling, general and administrative expenses increased by \$27.4 million to \$129.5 million for the three months ended September 30, 2022. See Note 8 Long-term Debt in the Notes to Unaudited Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional details regarding the conversion of debt in the three months ended September 30, 2022.

Interest Income

Interest income was \$5.0 million March 31, 2024, from \$102.1 million for the three months ended September 30, 2023 March 31, 2023, an increase of \$2.2 million, compared to \$2.8 million for the three months ended September 30, 2022. The increase in interest income was primarily attributable to increased money market interest rates during the three months ended September 30, 2023.

Interest Expense

Interest expense was \$7.3 million for the three months ended September 30, 2023, a decrease of \$0.6 million, compared to \$7.9 million for the three months ended September 30, 2022. The decrease is primarily due to lower outstanding principal amount of the Convertible Notes.

Other (Expense)/Income, Net

Other expense was \$0.6 million, for the three months ended September 30, 2023, as compared to other income of \$0.1 million for the three months ended September 30, 2022. The increase was primarily due to foreign currency revaluation losses.

Income Tax Expense

Income tax expense was \$0.2 million for the three months ended September 30, 2023, decrease of \$0.2 million, compared to \$0.4 million for the three months ended September 30, 2022. The decrease primarily pertained to a decrease in U.S. taxable income, driven in part by lower research and development capitalization.

Nine Months Ended September 30, 2023 and 2022 (in thousands, except percentages)

	For the Nine Months Ended				Change	Change		
	September 30,		2023	2022				
	\$	%						
Revenue:								
Product revenue, net	\$ 227,626		\$ 45,439	\$ 182,187		401 %		
Licensing and other revenue	22,588		7,320	15,268		209 %		
Total revenue:	250,214		52,759	197,455		374 %		
Operating expenses:								
Cost of sales	38,598		2,711	35,887		1,324 %		
Research and development	285,105		287,813	(2,708)		(1 %)		
General and administrative	359,114		192,795	166,319		86 %		
Total operating expenses:	682,817		483,319	199,498		41 %		
Net operating loss	(432,603)		(430,560)	(2,043)		0 %		
Loss on conversion of debt	—		(32,890)	32,890		(100 %)		
Interest income	16,385		4,339	12,046		278 %		
Interest expense	(22,179)		(24,888)	2,709		(11 %)		
Other (expense)/income, net	(946)		(42)	(904)		2,152 %		
Net loss before taxes	\$ (439,343)		\$ (484,041)	\$ 44,698		(9 %)		
Income tax expense	709		2,140	(1,431)		(67 %)		
Net loss	\$ (440,052)		\$ (486,181)	\$ 46,129		(9 %)		

Product Revenue, Net

Our product revenue, net is derived from EMPAVELI sales in the United States which was launched in May 2021 and SYFOVRE sales in the United States which was launched in March 2023. We recognized \$227.6 million and \$45.4 million of net product revenue for the nine months ended September 30, 2023 and 2022, respectively. The net product revenue of \$227.6 million for the nine months

32

Table of Contents

ended September 30, 2023, consisted of \$66.6 million in net product revenue from sales of EMPAVELI and \$161.0 million in net product revenue from sales of SYFOVRE.

Licensing and Other Revenue

Licensing and other revenue of \$22.6 million during the nine months ended September 30, 2023 included \$10.8 million in revenue for product supplied to Sobi, \$6.8 million in royalty revenue from Sobi and \$5.0 million from collaboration with Sobi. Licensing and other revenue of \$7.3 million during the nine months ended September 30, 2022 included \$5.7 million in revenue for product supplied to Sobi and \$1.6 million in royalty revenue from Sobi.

Cost of Sales

Cost of sales was \$38.6 million for the nine months ended September 30, 2023 and \$2.7 million for the nine months ended September 30, 2022. The increase in cost of sales was primarily driven by a \$12.8 million increase due to increased product volume from commercial sales and product provided under our patient assistance programs, a \$7.1 million increase from cost of supply provided under our collaboration with Sobi, a \$6.9 million increase in royalty expense, a \$6.5 million increase due to the achievement of various sales-based milestones, a \$0.5 million increase due to a sublicense fee, and a \$2.1 million increase in expenses incurred related to excess or obsolete inventory.

In addition, prior to receiving FDA approval for EMPAVELI and SYFOVRE, the costs associated with the manufacturing of EMPAVELI and SYFOVRE inventory were expensed as incurred as research and development expense. This resulted in inventory being sold for the nine months ended September 30, 2023 and 2022 for which a portion of the costs had been previously expensed prior to FDA approval. We expect this to continue to impact the cost of sales as the remaining pre-FDA approval inventory is sold to customers.

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the nine months ended September 30, 2023 and 2022 (in thousands, except percentages):

	For the Nine Months Ended			
	September 30,		Change	Change
	2023	2022		
Clinical trial costs	\$ 64,998	\$ 68,929	\$ (3,931)	(6 %)
Compensation and related personnel costs	131,647	117,626	14,021	12 %
Contract manufacturing	13,771	34,922	(21,151)	(61 %)
Sobi development milestone	—	(4,993)	4,993	(100 %)
Research/innovation costs	22,871	15,296	7,575	50 %
Other development costs	41,812	46,122	(4,310)	(9 %)

Pre-clinical study expenses	7,164	8,209	(1,045)	(13%)
Device development expenses	2,842	1,702	1,140	67%
Research and development expenses	285,105	287,813	(2,708)	(1%)

Research and development expenses decreased by \$2.7 million to \$285.1 million for the nine months ended September 30, 2023 from \$287.8 million for the nine months ended September 30, 2022, a decrease of 1%. The decrease was primarily attributable to a decrease of \$3.9 million in clinical trial costs due to the completion of our Phase 3 DERBY and OAKS trials, a decrease of \$21.2 million in contract manufacturing expenses due primarily to the timing of drug supply and analytical activity, and a decrease of \$4.3 million in other development costs and a decrease of \$1.0 million on pre-clinical study expenses. In addition, there was no contra research and development expenses recorded under the Sobi collaboration agreement for the nine months ended September 30, 2023 as compared to \$5.0 million for the nine months ended September 30, 2022. The decreases were partially offset by an increase of \$14.0 million in personnel related costs due to having more employees in the nine months ended September 30, 2023, an increase of \$7.6 million in research and innovation costs, an increase of \$1.1 million in device development expenses.

General and Administrative Expenses

General and administrative expenses increased by \$166.3 million to \$359.2 million for the nine months ended September 30, 2023, from \$192.8 million for the nine months ended September 30, 2022, an increase of 86% 27%. The increase was primarily attributable to an increase in employee personnel related costs of \$62.8 million \$7.4 million, an increase in professional and consulting fees and general commercial preparation activities of \$94.4 million, an increase in travel related expenses of \$4.2 million, \$17.7 million and higher office costs of \$4.8 million \$2.7 million, and an increase in director stock option compensation of \$0.3 million. The increase was which were partially offset by lower a decrease of \$0.2 million in travel expenses and a decrease of \$0.2 million in insurance expenses of \$0.2 million. The increase in employee personnel related costs of \$62.8 million \$7.4 million consisted of a \$54.9 million \$4.4 million increase in salaries and benefits primarily

33

Table of Contents

due to the higher number of employees in the period, and an increase of \$9.5 million \$3.3 million related to stock compensation expense associated with the grant of stock options and restricted stock units to employees, partially offset by a decrease of \$1.6 million \$0.3 million in recruiting expenses. The increase in other professional and consulting fees and general commercial preparation activities of \$94.4 million \$17.7 million consisted primarily related to higher commercialization related activity of \$88.7 million, and an increase \$18.0 million primarily due to the commercial launch of SYFOVRE in March 2023, partially offset by a decrease in general professional fees of \$5.7 million \$0.3 million.

Loss on Conversion of Debt

Loss on conversion Interest Income

27

Table of debt Contents

Interest income was \$32.9 million for the nine months ended September 30, 2022. See Note 8 Long-term Debt in the Notes to Unaudited Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q for additional details regarding the conversion of debt in the three months ended September 30, 2022.

Interest Income

Interest income was \$16.4 million for the nine months ended March 31, 2024, a decrease of \$2.1 million, compared to \$5.4 million for the nine months ended September 30, 2023, an increase of \$12.0 million compared to \$4.4 million for the nine months ended September 30, 2022. The increase in interest income was primarily attributable to increased money market interest rates and decreased investments during the nine months ended September 30, 2023.

Interest Expense

Interest expense was \$22.2 million for the nine months ended September 30, 2023, a decrease of \$2.7 million compared to \$24.9 million for the nine months ended March 31, 2024 and \$7.5 million for the nine months ended September 30, 2022. The decrease is primarily due to lower outstanding principal amount and a decrease in the balance of our convertible notes.

Other (Expense)/Income, Net

Other expense income/(expense), net, was \$0.9 million for the nine months ended March 31, 2024 and \$0.3 million for the nine months ended September 30, 2023 as compared to other income of \$0.1 million for the nine months ended September 30, 2022.

Income Tax Expense

Income tax expense was \$0.7 million for the nine months ended September 30, 2023.

The decrease primarily pertained to a decrease in U.S. taxable income, driven in part by lower research and development capitalization.

state taxes.

Liquidity and Capital Resources

Sources of Liquidity

To date, we have financed our operations primarily through \$1.6 billion in net proceeds from public offerings of our common stock including our initial public offering, or IPO, and pre-funded warrants to purchase common stock, \$535.8 million in net proceeds from offerings of our convertible notes, Convertible Notes, a \$250.0 million up-front payment and a \$65.0 million development reimbursement payments from Sobi pursuant to the Sobi collaboration agreement, \$112.6 million in proceeds from the private placement of shares of our convertible preferred stock prior to our IPO, \$140.0 million under the SFJ agreement, \$20.0 million in proceeds from borrowings under a term loan facility with Silicon Valley Bank, and \$7.0 million in proceeds from our issuance and sale of a promissory note. We have repaid the term loan facility and the promissory note in full, and have exchanged \$425.4 million of aggregate principal amount of our convertible notes for shares of our common stock.

In May 2020, we completed a private offering of \$300.0 million aggregate principal amount of convertible notes, or the 2020 Convertible Notes and, together with the 2019 Convertible Notes, the Convertible Notes. We received net proceeds of approximately \$322.9 million, which included accrued interest from March 15, 2020 to, but not including May 12, 2020, and the initial purchasers' discounts and commissions and offering costs of \$6.0 million.

In January 2021, November 2023, we entered into separate, privately negotiated exchange agreements a sales agreement, or the sales agreement, with certain holders of our 2019 Convertible Notes. Under the terms of these exchange agreements, the holders exchanged approximately \$126.1 million in aggregate principal amount of 2019 Convertible Notes held by them for an aggregate of 3,906,869 Cowen and Company, LLC, or Cowen, as agent, pursuant to which we may offer and sell shares of our common stock. These exchange transactions closed stock having an aggregate offering from of up to \$300.0 million from time to time. Any sales made under the sales agreement will be made at market prices by any method that is deemed to be an "at the market offering" as defined in January 2021.

In July 2021, we entered into separate, privately negotiated exchange agreements Rule 415(a)(4) promulgated under the Securities Act of 1933. Any sales under the sales agreement will be made pursuant to modify the conversion terms with certain holders our registration statement on Form S-3, which became effective on February 22, 2023. We agreed to pay Cowen compensation of up to 3.0% of the Convertible Notes. Under the terms of these exchange agreements, the holders exchanged approximately \$201.1 million in aggregate principal amount gross proceeds of the Convertible Notes held by them for an aggregate sale of 5,992,217 shares of our common stock. These exchange transactions closed in July 2021.

34

Table of Contents

In July 2022, we entered into separate, privately negotiated exchange agreements with certain holders of Convertible Notes pursuant to which made under the holders exchanged approximately \$98.1 million in aggregate principal amount of Convertible Notes held by them for an aggregate of 3,027,018 shares of common stock. These exchange transactions closed in August 2022, sales agreement. We did not make any sales under the sales agreement during the three months ended March 31, 2024.

In February 2023, we issued and sold 4,007,936 shares of our common stock and, in lieu of common stock to investor investors who so chose, pre-funded warrants to purchase 2,380,956 shares of our common stock in a follow-on offering, including 833,333 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock. The price to the public of the shares of common stock was \$63.00 per share and the price to the public of the pre-funded warrants was \$62.9999 per pre-funded warrant. The pre-funded warrants have an exercise price equal to \$0.0001 per share and do not expire. The pre-funded warrants were accounted for as equity instruments. We received total net proceeds of \$384.4 million, after deducting underwriting discounts and commissions of \$18.8 million and offering cost of \$0.3 million.

The We entered into agreements with the capped call transactions that we entered into concurrently with the issuance of the Convertible Notes are expected generally counterparties to reduce the potential dilution to our common stock upon any conversion of the Convertible Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted convertible notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms unwind a portion of the capped call transactions is greater than on February 27, 2024. The unwind agreements applied to the strike price portion of the capped call transactions which is initially \$39.4625, in a notional amount corresponding to the conversion \$426.1 million principal amount of Convertible Notes that we held in treasury as of December 31, 2023 or have been previously converted. The unwind transactions was settled based on the volume-weighted average price of our common stock over a 7-day averaging period beginning on and including February 27, 2024. The settlement of the Convertible Notes, and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such Convertible Notes. If, however, the market unwind transactions was completed on March 8, 2024 at volume-weighted average price per share of our common stock, as measured under the terms \$64.11, which resulted in cash proceeds to us of \$98.8 million. As of March 31, 2024, the capped call

transactions exceeds \$63.14, the cap price remaining is a notional amount corresponding to \$93.9 million principal amount of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset Convertible Notes.

[Table of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.](#) [Contents](#)

Refer to Note 8 Long-term Debt in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item I of this Quarterly Report on Form 10-Q for additional information regarding the convertible notes and capped call transactions. In addition, our cash deposits may exceed federally insured limits, and we are exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC).

Cash Flows

The following table provides information regarding our cash flows for the **nine****three** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** (in thousands):

	For the Nine Months Ended September 30,	
	2023	2022
Net cash used in operating activities	\$ (496,860)	\$ (373,001)
Net cash (used in) investing activities	(678)	(64,236)
Net cash provided by financing activities	398,412	381,605
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(449)	(675)
Net decrease in cash, cash equivalents and restricted cash	\$ (99,575)	\$ (56,307)

	For the Three Months Ended March 31,	
	2024	2023
Net cash used in operating activities	\$ (132,983)	\$ (177,620)
Net cash used in investing activities	(293)	(259)
Net cash provided by financing activities	108,212	391,106
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(209)	56
Net (decrease) increase in cash, cash equivalents and restricted cash	\$ (25,273)	\$ 213,283

Net Cash Used in Operating Activities

Net cash used in operating activities was **\$496.9 million** **\$133.0 million** for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** and consisted primarily of a net loss of **\$440.1 million** **\$66.4 million** adjusted for **\$100.8 million** **\$36.9 million** of non-cash items, including share-based compensation expense of **\$79.7 million** **\$30.3 million**, depreciation expense of **\$1.3 million**, **\$0.4 million** and accretion of discount to the development liability of **\$19.5 million** **\$6.1 million**. Further, it **includes** **included** a net increase in operating assets and liabilities of **\$161.3 million** **\$103.5 million**, which **included** **an increase** **was driven by** **increases** in accounts receivable of **\$161.5 million** **\$61.4 million**, an increase in inventory of **\$14.9 million**, an increase in prepaid assets of **\$4.3 million**, a decrease in other current assets of **\$10.7 million**, a decrease in accounts payable and accrued expenses of **\$19.5 million** **\$37.1 million**, and an increase in accrued expenses deferred revenue of **\$23.1 million** **\$3.6 million**.

Net cash used in operating activities was **\$373.0 million** **\$177.6 million** for the **nine** **three** months ended **September 30, 2022** **March 31, 2023** and consisted primarily of a net loss of **\$486.2 million** **\$177.8 million** adjusted for **\$124.4 million** **\$35.9 million** of non-cash items, including share-based compensation expense of **\$66.8 million**, a loss on early exchange of debt of **\$32.9 million**, the forfeiture of accrued interest in the exchange of the Convertible Notes of **\$1.3 million** **\$28.8 million**, depreciation expense of **\$1.2 million**, **\$0.4 million** and accretion of discount to the development liability of **\$20.1 million**, and other liabilities of **\$1.9 million** **\$6.6 million**. Further, it includes a net decrease in current operating assets of **\$1.5 million**, an increase in other assets of **\$15.9 million** **\$6.5 million**, a decrease in accounts payable of **\$4.4 million** **\$5.9 million** and a decrease in accrued expenses of **\$21.3 million** **\$23.4 million**.

35

Table of Contents

Net Cash Used in Investing Activities

Net cash used in investing activities during the **nine** **three** months ended **September 30, 2023** **March 31, 2024** was **\$0.7 million** **\$0.3 million** primarily due primarily to purchases of fixed assets.

Net cash used in provided by investing activities during the **nine** **three** months ended **September 30, 2022** **March 31, 2023** was **\$64.2 million** **\$0.3 million** primarily due to **\$331.9 million** in purchases of marketable securities, partially offset by **\$268.3 million** in proceeds from maturity of marketable proceeds, fixed assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was **\$398.4 million** **\$108.2 million** during the **nine** **three** months ended **September 30, 2023** **March 31, 2024** and consisted primarily of proceeds from the settlement of capped call unwind transactions of **\$98.8 million** and **\$9.5 million** of proceeds from the exercise of stock options.

Net cash provided by financing activities was **\$391.1 million** during the three months ended March 31, 2023 and consisted primarily of proceeds from the follow-on common stock and pre-funded warrant offering in March 2023 of **\$384.4 million**, **\$45.9 million** **\$17.7 million** proceeds upon from the exercise of stock options and **\$3.7 million** proceeds from the issuance of our common stock under the employee stock purchase plan partially offset by payments of **\$24.5 million** for the development liability as well as the payments of employee tax withholding related to equity-based compensation of **\$11.1 million** **\$11.0 million**.

Net cash provided by financing activities was **\$381.6 million** during the nine months ended September 30, 2022 and consisted primarily of proceeds from the follow-on common stock offering in March 2022 of **\$380.1 million**, **\$19.4 million** proceeds upon the exercise of stock options and **\$2.6 million** proceeds from the issuance of common stock under the employee stock purchase plan partially offset by

payments of \$16.5 million for the development liability as well as \$4.0 million for the payments of employee tax withholding related to equity-based compensation.

Funding Requirements

Our corporate restructuring plan includes cost reduction initiatives that are expected to result in cost savings in the near-term. In connection with restructuring plan we We expect to continue incur expenses to support our ongoing commercial activities related to product manufacturing, marketing, sales and distribution of EMPAVELI for PNH and SYFOVRE for GA. In addition, we expect to continue to incur expenses as we prioritize the ongoing development of systemic pegcetacoplan and focus our research initiatives on high potential opportunities.

We believe that our cash and cash equivalents as of September 30, 2023 March 31, 2024, along together with the cash anticipated to that we anticipate will be generated from sales of EMPAVELI and SYFOVRE as well as the remaining committed development reimbursement payment from Sobi, will be sufficient to fund our current projected operating expenses and capital expenditure requirements into for at least the second quarter next 12 months, as well as our anticipated longer-term cash requirements and obligations. Our expectations regarding

29

Table of 2025. We have Contents

our short-term and long-term funding requirements are based this estimate on assumptions that may prove to be wrong, and we may use our available need additional capital resources sooner than we currently expect. to fund our operating plans and capital expenditure requirements.

We are devoting substantial resources to the building of a commercial infrastructure for SYFOVRE for GA. We are also devoting additional substantial resources to the development of our product candidates. We will need to seek additional funding to conduct these activities. Because of the numerous risks and uncertainties associated with the commercialization of EMPAVELI and SYFOVRE and development of other product candidates, and because the extent to which we may enter into collaborations with third parties for the development any of these product candidates activities is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research, development and development of our product candidates. commercialization. Our future funding requirements and long-term capital requirements will depend on many factors, including:

- our ability to continue to successfully commercialize and sell EMPAVELI and SYFOVRE in the United States;
- the cost of and our ability to submit applications for obtain regulatory approval approvals of SYFOVRE outside of the United States and continue to build a commercial infrastructure for SYFOVRE for GA in the United States and worldwide;
- the cost of and our ability to effectively establish and maintain, the commercial infrastructure and manufacturing capabilities required to support the continued commercialization of EMPAVELI, systemic pegcetacoplan and SYFOVRE and any other products for which we receive marketing approval including product sales, medical affairs, marketing, manufacturing and distribution;
- the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for system

pegcetacoplan, SYFOVRE and our other product candidates;

- our ability to maintain a productive collaborative relationship with Sobi with respect to systemic pegcetacoplan, including our ability to achieve milestone payments under our agreement with Sobi;
- our ability to identify additional collaborators for any of our product candidates and the terms and timing of any collaboration agreement that we may establish for the development and any commercialization of such product candidates;
- the number and characteristics of future product candidates that we pursue and their development requirements;

[Table of Contents](#)

- the outcome, timing and costs of clinical trials and of seeking regulatory approvals of pegcetacoplan in other jurisdictions and indications and other product candidates we may pursue;
- the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
- subject to receipt of marketing approval, revenue, if any, received from commercial sales of pegcetacoplan in other jurisdictions and indications and our other product candidates;
- our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
- the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;
- the effect of competing technological and market developments;
- the effect of public health crises, including pandemics and epidemics, on the healthcare system and the economy generally and on our clinical trials and other operations specifically;
- our ability to obtain adequate reimbursement for EMPAVELI and SYFOVRE in the United States or any other product we commercialize; and
- the costs of operating as a public company.

Until such time, if ever, as If our cash and cash equivalents, and cash generated from sales of EMPAVELI and SYFOVRE are not sufficient to fund our planned expenditures, we can generate substantial product revenues, we expect will need to finance our cash needs through a combination external sources of funds, which may include equity offerings, debt financings, collaborations, strategic alliances and or licensing arrangements. We currently do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders' ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. Debt financing, if available, would result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.

If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to generate sufficient funds from sales of EMPAVELI and SYFOVRE, or raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product

development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

[Table of Contents](#)

Contractual Obligations

The disclosure of our contractual obligations and commitments is set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations” in our **2022** **2023** Annual Report on Form 10-K. See Note **14** **13** Commitments and Contingencies in the Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item I of this Form 10-Q for a discussion of obligations and commitments.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. As of **September 30, 2023** **March 31, 2024**, we had cash and cash equivalents of **\$452.4 million** **\$325.9 million**, consisting primarily of money market funds and U.S. Government obligations. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

[Table of Contents](#)

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(f) and 15d-15(e) under the Exchange Act of 1934 as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of **September 30, 2023** **March 31, 2024**.

Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended **September 30, 2023** **March 31, 2024** that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

38 31

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

On August 2, 2023, Judith M. Soderberg filed a complaint See Note 13 Commitments and Contingencies in the United States District Court for the District Notes to Unaudited Condensed Consolidated Financial Statements in Part I, Item I of Delaware on behalf of a class of all persons and entities who purchased or otherwise acquired Apellis common stock between January 28, 2021, and July 28, 2023, inclusive, naming as defendants the Company, President and Chief Executive Officer Cedric Francois, Chief Financial Officer and Treasurer Timothy Sullivan, and former Chief Medical Officer Federico Grossi (the "Complaint"). On October 23, 2023, the Court appointed Ray Peleckas and Michigan Laborers' Pension Fund together as Co-Lead Plaintiffs and assigned the action the caption In re Apellis Pharmaceuticals, Inc. Securities Litigation, Case 1:23-cv-00834-MN. The Complaint alleges, among other things, that the defendants violated Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by misrepresenting and/or omitting certain material facts related to the design of SYFOVRE's clinical trials and the risks associated with SYFOVRE's commercial adoption. The Complaint seeks, among other relief, compensatory damages and equitable relief in favor of the alleged class of plaintiffs against all defendants, including interest, and reasonable costs and expenses incurred by plaintiffs, including

attorneys' and expert fees. On October 2, 2023, the defendants moved to transfer the action to the United States District Court for the District of Massachusetts. The Court has not yet ruled on this motion. Form 10-Q. The outcome of the matter described above cannot be predicted with certainty. However, the Company intends to vigorously defend against the litigation.

Item 1A. Risk Factors.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors set forth below and those discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, which could materially affect our business, financial condition or future results. The risk factors disclosure below and in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023 is qualified by the information that is described in this Quarterly Report on Form 10-Q. The risks described below and in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023 are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

We or others may later discover that EMPAVELI or SYFOVRE is less effective than previously believed or causes safety issues that were not previously identified, which could compromise our ability, or that of our collaborators, to market the product.

Clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of our collaborators, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify safety issues that may be observed once the product has been commercialized. If safety problems occur or are identified after EMPAVELI or SYFOVRE or one of our products, if any, reaches the market, the FDA or comparable non-U.S. regulatory authorities may require that we amend the labeling of our product, recall our product, or even withdraw approval for our product.

A small number of patients treated with SYFOVRE in the real world have experienced retinal vasculitis, a severe form of intraocular inflammation. All suspected retinal vasculitis events reported to us are independently evaluated and adjudicated by two external sources: a panel of four retina/uveitis experts and an independent reading center as well as our internal safety and medical teams. We are working with the retinal community to investigate potential contributing factors. We will continue to submit all adverse events reported to us to the FDA consistent with reporting guidelines for drug manufacturers.

In October 2023, we provided an update on the events of retinal vasculitis following SYFOVRE treatment. Based upon our review of these events after the distribution of more than 100,000 vials of SYFOVRE after its commercial launch, we believe that the rate of incidence of retinal vasculitis is approximately 0.01% per injection.

In August 2023, we recommended that practitioners discontinue use of any injection kits that contain 19-gauge filter needles due to internal structural variations identified in the 19 gauge inch filter needle. We now exclusively distribute injection kits with the 18-gauge filter needle. A causal relationship has not been established between the structural variations in this 19-gauge filter needle and the events of retinal vasculitis, and there can be no assurance that this change will affect the rate of adverse events following SYFOVRE treatment.

We cannot provide any assurances that the FDA and the retinal community will continue to believe that the expected benefits of SYFOVRE treatment outweigh its potential risks to patients following these reported events or that our applications for marketing

[Table of Contents](#)

approval of SYFOVRE in other jurisdictions will not be adversely impacted. A change in the perception of the benefit/risk profile of SYFOVRE may reduce market acceptance of the product and our product revenues may be adversely affected.

If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes safety issues that were not previously identified, such as the reported events of retinal vasculitis following SYFOVRE treatment, any of the following events could occur:

- the target patient population may be less willing to try, and physicians may be less willing to prescribe, the product;
- regulatory authorities may withdraw their approval of the product or seize the product;
- we, or our collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;
- additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;
- we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
- regulatory authorities may require the addition of labeling statements, such as a "black box" warning or a contraindication;
- we, or our collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;
- we, or our collaborators, could be sued and held liable for harm caused to patients;
- the product may become less competitive; and
- our reputation may suffer.

Any of these events could harm our business and operations, affect sales of our products and negatively impact our stock price.

Our corporate restructuring and workforce reduction announced in August 2023, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.

In August 2023, we announced that we were conducting a corporate restructuring and cost savings initiatives involving a headcount reduction of approximately 225 employees, or approximately 25% of our then current workforce. We have estimated that the restructuring and related cost reduction initiatives will result in up to \$300 million in total cost savings through 2024. However, these estimates are subject to several assumptions, and actual results may differ. We may not realize, in full or in part, the anticipated benefits and savings from this restructuring due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected cost savings from the announced restructuring, our operating results and financial condition could be adversely affected. The workforce reduction may be disruptive to our operations and could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale, as well as result in weaknesses in our infrastructure and operations, and may increase the risk that we become unable to comply with legal and regulatory requirements. Our workforce reductions could also harm ability to attract and retain qualified management, scientific, clinical, and/or manufacturing personnel. Any failure to attract or retain qualified personnel could prevent us from successfully commercializing SYFOVRE and EMPAVELI and may adversely affect the development of our product candidates.

We have substantial accounts receivable, and any delays in collecting accounts receivable or the failure to collect accounts receivable could have a material adverse effect on our cash flows and results of operations.

Our accounts receivable balance was \$169.3 million as of September 30, 2023. While we monitor the financial performance and creditworthiness of our customers and provide reserves against trade receivables for expected credit losses that may result from a customer's failure to pay, no assurances can be made that we will not experience delays in collecting payments, that we will collect the payments due to us or that our reserves will be sufficient. Any failures to receive cash payments due to us could have a material adverse effect on our results of operations and cash flows.

We and certain of our current and former executive officers were named as defendants in lawsuits that could result in substantial costs and divert management's attention.

We and certain of our current and former executive officers were named as defendants in a lawsuit initiated in August 2023 that alleges that we and certain of our officers misrepresented and/or omitted certain material facts related to the design of SYFOVRE's clinical trials and the risks associated with SYFOVRE's commercial adoption. The Complaint seeks, among other relief, compensatory damages and equitable relief in favor of the alleged class of plaintiffs against all defendants, including interest, and reasonable costs and expenses incurred by plaintiffs, including attorneys' and expert fees.

40

[Table of Contents](#)

We are unable, however, to predict the outcome of these matters with certainty. The litigation, including in responding to discovery requests, caused our management to divert time and attention to the litigation and could adversely impact our reputation, and if the litigation remains protracted, could further divert management attention and resources from other priorities, including the execution of our business plan and strategies that are important to our ability to grow our business, any of which could have a material adverse effect on our business.

41

[Table of Contents](#)

Item 5. Other Information.

The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K):

Name (Title)	Action Taken		Nature of Trading Arrangement	Duration of Trading Arrangement		Aggregate Number of Securities
	(Date of Action)	Type of Trading Arrangement		Trading Arrangement	Duration of Trading Arrangement	
David Watson	Termination	Rule 10b5-1 trading arrangement				
General Counsel	8/01/2023	Sale	(1)			(1)
Pascal Deschatelets	Termination	Rule 10b5-1 trading arrangement				
Chief Scientific Officer	8/02/2023	Sale	(2)			(2)
				Until 3/15/2024, or such earlier date upon which all transactions are completed		
Pascal Deschatelets	Adoption	Rule 10b5-1 trading arrangement			Up to	
Chief Scientific Officer	8/03/2023	Sale	or expire without execution		369,022 shares	
				Until 2/29/2024, or such earlier date upon which all transactions are completed		
Jeffrey Eisele						
Chief Development Officer	Adoption	Rule 10b5-1 trading arrangement				
	8/15/2023	Sale	or expire without execution		Up to 63,683 shares	

Cedric Francois	Termination	Rule 10b5-1 trading arrangement	Sale	(3)	(3)
President and Chief Executive Officer	8/20/2023				
Nur Nicholson					
Chief Technical Operations	Termination	Rule 10b5-1 trading arrangement	Sale	(4)	(4)
Nur Nicholson	9/11/2023			Until 12/27/2024, or such earlier date upon which all transactions are completed	
Chief Technical Operations	Adoption	Rule 10b5-1 trading arrangement	Sale	or expire without execution	Up to 67,000 shares
	9/12/2023				

32

- (1) This trading plan related to 26,555 shares of our common stock and had a scheduled expiration date of 12/29/2023.
- (2) This trading plan related to 138,214 shares of our common stock and had a scheduled expiration date of 3/28/2024.
- (3) This trading plan related to 300,000 shares of our common stock and had a scheduled expiration date of 12/04/2023.
- (4) This trading plan related to 67,000 shares of our common stock and had a scheduled expiration date of 6/07/2024.

42

Table of Contents

Name (Title)	Action Taken		Nature of Trading		Aggregate Number of Securities
	(Date of Action)	Type of Trading Arrangement	Trading Arrangement	Duration of Trading Arrangement	
Alec Machiels	Adoption	Rule 10b5-1 trading arrangement		Until 11/28/2025, or such earlier date upon which all transactions are completed or expire without execution	Up to 18,000 shares
Director	2/29/2024		Sale		
David Watson	Adoption	Rule 10b5-1 trading arrangement		Until 2/28/2025, or such earlier date upon which all transactions are completed or expire without execution	Up to 23,872 shares
General Counsel	2/29/2024		Sale		
Mark DeLong				Until 2/28/2025, or such earlier date upon which all transactions are completed or expire without execution	Up to 24,799 shares
Chief Business & Strategy Officer	Adoption	Rule 10b5-1 trading arrangement	Sale		
	3/1/2024				

A. Sinclair Dunlop (1) Independent Director	Adoption 3/2/2024	non-Rule 10b5-1 trading arrangement	Sale	Until 12/31/2024, or such earlier date upon which all transactions are completed or expire without execution	Up to 174,000 shares
Cedric Francois President and Chief Executive Officer	Adoption 3/8/2024	Rule 10b5-1 trading arrangement	Sale	Until 5/30/2025 or such earlier date upon which all transactions are completed or expire without execution	Up to 592,034 shares
Caroline Baumal Chief Medical Officer	Adoption 3/13/2024	Rule 10b5-1 trading arrangement	Sale	Until 12/31/2024 or such earlier date upon which all transactions are completed or expire without execution	Up to 6,136 shares
Jeffrey R Eisele Chief Development Officer	Adoption 3/15/2024	Rule 10b5-1 trading arrangement	Sale	Until 2/28/2025 or such earlier date upon which all transactions are completed or expire without execution	Up to 207,256 shares
James Chopas Vice President, Corporate Controller and Chief Accounting Officer	Adoption 3/18/2024	Rule 10b5-1 trading arrangement	Sale	Until 8/30/2024 or such earlier date upon which all transactions are completed or expire without execution	Up to 4,000 shares
Karen L Lewis Chief People Officer	Adoption 3/19/2024	Rule 10b5-1 trading arrangement	Sale	Until 3/31/2025, or such earlier date upon which all transactions are completed or expire without execution	Up to 101,422 shares
Nur Nicholson Chief Technical Operations Officer	Adoption 3/30/2024	Rule 10b5-1 trading arrangement	Sale	Until 11/15/2024, or such earlier date upon which all transactions are completed or expire without execution	Up to 28,747 shares

(1) The non-Rule 10b5-1 trading plan relates to Epidarex Capital I LP, an affiliated entity of the named director.

[Table of Contents](#)

Item 6. Exhibits.

Exhibit

Description

Number	
31.1*	<u>Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2*	<u>Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1*	<u>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2*	<u>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Apellis Pharmaceuticals, Inc.

Date: **November 1, 2023** **May 7, 2024**

By: /s/ Cedric Francois

Cedric Francois

President and Chief Executive Officer
(principal executive officer)

Date: **November 1, 2023** **May 7, 2024**

By: /s/ Timothy Sullivan

Timothy Sullivan

Chief Financial Officer and Treasurer
(principal financial officer)

44 35

Exhibit 31.1

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND
15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002**

I, Cedric Francois, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Apellis Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 1, 2023** May 7, 2024

By: /s/ Cedric Francois

Cedric Francois

Chief Executive Officer

Exhibit 31.2

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULES 13A-14(A) AND
15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002**

I, Timothy Sullivan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Apellis Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the Quarterly Report on Form 10-Q of Apellis Pharmaceuticals, Inc.

the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) (Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 1, 2023** **May 7, 2024**

By: /s/ Timothy Sullivan

Timothy Sullivan

Chief Financial Officer and Treasurer

Exhibit 32.1

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Apellis Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending **September 30, 2023** **March 31, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Cedric Francois, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: **November 1, 2023** **May 7, 2024**

By: /s/ Cedric Francois

Cedric Francois

President and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Apellis Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending **September 30, 2023** **March 31, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Timothy Sullivan, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: **November 1, 2023** **May 7, 2024**

By: /s/ Timothy Sullivan

Timothy Sullivan

Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.